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ACE-inhibitors: Angiotensin- converting enzyme inhibitors 
ARBs: Angiotensin II receptor blockers 
AFM: Acute fulminant myocarditis 
BP: Blood pressure 
Mean BP: Mean blood pressure 
CCF: Congestive cardiac failure 
CHIP: Child healthcare problem identification programme 
CI: Confidence interval 
CK: Creatinine kinase 
CMV: Cytomegalovirus 
CMV VL: Cytomegalovirus viral load 
CMP: Calcium, magnesium and phosphate 
CPAP: Continuous positive airway pressure 
CPR: Cardiopulmonary resuscitation 
CRP: C-reactive protein 
CTR: Cardiothoracic ratio 
CXR: Chest X-ray/chest radiograph 
DCMO: Dilated cardiomyopathy 
DISA: Distributed Information System Architecture 
DOB: Date of birth 
ECG: Electrocardiogram 
ECM: Enterprise Content Management 
ECHO: Echocardiography 
ECMO: Extracorporeal membrane oxygenation 
EEG: Electroencephalogram 
EF: Ejection fraction 
EMB: Endomyocardial biopsy 
ESBL: Extended-spectrum-beta-lactamases 
ESR: Erythrocyte sedimentation rate 
GCS: Glasgow coma scale 
GFR: Glomerular filtration rate 
HIV: Human immunodeficiency virus 
HHV-6: Human Herpes Virus-6 
HR: Heart rate 
ICU: Intensive care unit 
IDCM: Idiopathic dilated cardiomyopathy 
IgM: Immunoglobulin M 
IPPV: Intermittent positive pressure ventilation 
IQR: Interquartile range 
ISFC: International Society and Federation of Cardiology 
IVIG: Intravenous immunoglobulin 
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JVP: Jugular venous pressure 
LFTs: Liver function tests 
LV: Left ventricular 
MC: Myocarditis 
MRI: Magnetic resonance imaging 
NEC: Necrotizing enterocolitis 
NHLS: National Health Laboratory System 
NPA: Nasopharyngeal aspirates 
PALS: Paediatric advanced life support 
PCR: Polymerase chain reaction 
PICU: Paediatric intensive care unit 
PM: Postmortem 
RCWMCH: Red Cross War Memorial Children’s Hospital 
RR: Respiratory rate 
SF: Shortening fraction 
TA: Tracheal aspirates   
TB: Tuberculosis 
TBH: Tygerberg Hospital 
UK: United Kingdom 
US: United States 
VAD: Ventricular assist device 
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Study definitions and reference values 
 
Myocarditis/ Dilated cardiomyopathy: For the purposes of this study these diagnoses were reviewed as a 
single entity. For this study a case was included if they had: 
• structurally normal heart with normal coronary arteries. 
As well as both A and B below: 
• A: On ECHO: systolic dysfunction with a left ventricular shortening fraction of less than 25% and/or an 
ejection fraction of less than 55%. 
AND/OR: Histopathological finding of myocarditis.  
AND 
• B: The cardiac dysfunction was not primarily due to septicemia or septic shock. 
 
Any abnormality on CXR: increased cardiothoracic ratio for age, signs of cardiac failure, plethora, pleural 
effusions, atelectasis/collapse or airway narrowing. Signs of cardiac failure on CXR included: increased 
cardiothoracic ratio, pulmonary plethora/pulmonary oedema and pleural effusions. 
Cardiovascular instability: combination of 1 or more of the following clinical entities: shock, poor 
perfusion, any hypotension recorded, raised lactate >3 or metabolic acidosis with a pH <7.35, thought to be 
due to poor perfusion or shock. 
Cardiac failure: clinicians’ assessment and documentation in the medical notes of “cardiac failure” or 
“congestive cardiac failure” OR mention of combination of clinical signs including a gallop rhythm, 
tachycardia, basal crackles and hepatomegaly. 
Clinical diagnosis of MC/DCMO: where children were admitted to TBH and the attending doctor made the 
clinical diagnosis of MC/DCMO, however the child died prior to an ECHO being done and to which no 
postmortem was consented. These cases were excluded from this study. 
Delay in diagnosis: markers of delay in presentation and diagnosis were whether children had longer 
duration of symptoms before presenting (>7 days), two or more healthcare visits prior to the diagnosis being 
made or were admitted for more than 24 hours to an alternate hospital with a different diagnosis (e.g. 
pneumonia) prior to referral. 
Depressed level of consciousness/coma: GCS: <8/15 not due to sedation. 
ECG abnormal: tachycardia for age, abnormal QTc, abnormal rhythm, abnormal axis, any chamber 
enlargement, any features of ischaemia. 
2 or more abnormalities on ECG: >2 of above signs. 
Further admissions: any further admissions to Tygerberg Hospital, having been discharged alive, and after 
the initial admission during which the diagnosis of acute myocarditis or DCMO was made. 
Idiopathic: for the purposes of this study; a case was categorized as “idiopathic” if they had a full workup 
that included a negative viral screen, a negative basic metabolic screen and a negative autoimmune screen 
and they had no clinical signs of nephritis nor signs of an arrhythmia; they were also not on 
chemotherapeutic agents. 
Increased cardiothoracic ratio (on CXR): increased cardiothoracic ratio for age: 
o Younger than 12 months of age  > 60%  
o 12 months and older >55% 
Inside Metro: immediate TBH drainage area including Khayelitsha. 
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Most recent clinical encounter: most recent date recorded of patient seen in any clinical area at Tygerberg 
Hospital. 
Not determined or incompletely investigated: cases were assigned to this cause category if they were not 
investigated fully i.e. did not have ALL of the following: a viral screen, a metabolic screen, an autoimmune 
screen and an ECG. 
Other respiratory support: nasal prongs, facemask oxygen of any form, CPAP, Bi-Pap. 
Outside Metro: outside the direct TBH drainage area e.g. Worcester, Paarl, Hermanus etc. 
Plethora on CXR: enlargement/increased pulmonary perfusion by opinion of paediatric pulmonologist on 
review of CXR. 
Poor perfusion: documentation in medical notes of “poor perfusion” or clinical entity where child had cool 
peripheries but did not qualify as “shock”. 
Prolonged QTc: QTc>470ms. 
Presumed viral myocarditis: for the purposes of this study: cases where there was a significant virus known 
to be associated with myocarditis, isolated on either PCR of TA/NPA, urine or on blood. The metabolic and 
autoimmune screens in these cases were negative and the ECG excluded an arrhythmia. 
QTc: QTc was calculated using the Fridericia's formula (using the QT divided by the cube-root of RR 
interval). 
Respiratory Viral Panel: tracheal aspirate and/or nasopharyngeal aspirate for multiplex PCR. 
Shock: documentation in the medical notes of  “shock”, being hypotensive for age or a combination of 
absent/poor peripheral pulses, a capillary refill time of more than 3 seconds, and cool peripheries. 
Systolic Hypotension: Systolic blood pressures below the lower limit of systolic blood pressure for age. 
Suggestive of CCF (CXR): cardiomegaly with signs of plethora. 
Tachypnoea for age: respiratory rate above the upper limit of respiratory rate for age. See table below. 
Tachycardia for age: heart rate above the upper limit of heart rate for age. See table below. 
Tachycardia on ECG: heart rate on ECG above the maximum heart rate for age. See table below 
Time to death: number of days from date of diagnosis of acute myocarditis or DCMO to date of death. 
Time to follow up: number of days from date of diagnosis of acute myocarditis or DCMO to the date of the 
most recent clinical encounter or death. 
Viral myocarditis: for the purposes of this study: a case where there was a significant virus known to be 
associated with myocarditis, isolated on either PCR of TA/NPA, urine or on blood. The metabolic and 
autoimmune screens in these cases were negative and the ECG excluded an arrhythmia. 
 
Age linked normal values for this study* 
 Tachycardia Tachypnoea Systolic Hypotention 
Birth Above 200 Above 60 Below 40 
Birth-28 days Above 200 Above 60 Below 60 
1 month-1 year Above 190 Above 53 Below 70 
1- 2 years Above 140 Above 37 70 + (age in years x2) 
3-5 years Above 120 Above 28 70 + (age in years 
6- 11 years  Above 118 Above 25 Below 90 
12-13 years Above 100 Above 20 Below 90 
*Adapted from the Paediatric Vital Sign Reference Chart -Pedscses.com PALS 2015 (1) 




Introduction: Approximately 27% of new cases of paediatric cardiac failure in well-resourced settings are due to 
abnormalities of the myocardium. Acute myocarditis and dilated cardiomyopathy (DCMO) may be clinically 
indistinguishable at presentation but are distinct diseases. The clinical presentations of myocarditis and DCMO can range 
from asymptomatic, to fulminant cardiac failure or sudden death. The diagnoses are dependent upon early clinical 
suspicion as cardiac failure is present in 90%-100% of cases and this is commonly misdiagnosed as respiratory disease. 
Viral infections (in the case of myocarditis) and the sequelae of viral myocarditis (in the case of DCMO) are the most 
important causes of myocardial failure, but there are a number of other infections and conditions as well as toxins that are 
implicated in both these diseases. The cause of myocardial failure may remain obscure, particularly if cases are not 
rigorously investigated. Entero- and adenoviruses remain important viral pathogens associated with viral myocarditis 
although there seems to be a viral shift with parvovirus B19 and herpes virus now being commonly implicated. Increasing 
sophistication of genetic and metabolic evaluations is reducing the number of idiopathic cases.  
Diagnostic tests are directed at confirming the diagnosis of myocardial dysfunction and identifying the cause. Chest 
radiographs (CXR) and electrocardiograms (ECG) are widely used initial investigations and are abnormal in above 90% 
of cases. Echocardiographic (ECHO) examination is used to confirm the diagnosis, exclude structural and other causes of 
cardiac failure and establish a baseline for follow-up. Polymerase chain reaction (PCR) can detect viral genomes in many 
tissues and PCR identification of viruses on respiratory specimens correlates well with those obtained from the 
myocardium. Supportive therapy focusing on treatment of fluid overload and under perfusion is the mainstay of care. 
Access to ventilatory support, extracorporeal membrane oxygenation (ECMO), ventricular assist devices (VAD) and 
cardiac transplantation has dramatically changed the outcomes in well-resourced settings where children who survive an 
initial hospitalization have survival at 1 year of 94% and 89% at 5 years. The predictors and risk factors for death are age 
(neonatal period and older age at presentation), congestive cardiac failure, lower shortening fraction (SF<15%) and 
ejection fraction (EF <30%) and in the case of DCMO the aetiology. Nearly all data on the outcome of children 
presenting with and treated for acute myocarditis and DCMO are reported from developed countries with sophisticated 
medical services and interventions. There is little data on the clinical presentation, course, outcomes and causes of 
myocarditis and DCMO in children in middle and low resourced settings, where high burdens of complicating infectious 
diseases including tuberculosis and HIV exist. A single study from South Africa reports only on children who required 
paediatric intensive care (PICU) and shows an initial hospital survival of 47% of children. There are no data on the 
longer-term outcomes. 
Aims and Objectives: The aim of this study is to investigate the clinical presentation, course and outcome; including 
morbidity and mortality of children with myocarditis and DCMO, and to attempt to determine factors that predict for 
outcome.  The results hope to guide local clinicians in developing guidelines for children, assist prognostication and 
potentially identify areas where management and the utilization of scarce resources can be improved. 
Methods: We conducted a retrospective descriptive review of children from birth to 13 years, diagnosed with acute 
myocarditis and DCMO from 1 January 2008 to 31 December 2015 at Tygerberg Hospital, a tertiary hospital in the 
Western Cape, South Africa. For the purposes of this study myocarditis and DCMO were studied as a single entity due to 
various complexities in separating these entities clearly and the continutuum/overlap that often pursues.  Inclusion criteria 
for this study were all patients with the diagnosis of myocarditis or DCMO, based on ECHO findings of an EF <55% 
and/or a SF <25%, or antemortem or postmortem histology. Children were excluded if there were structural or vascular 
abnormalities of the heart, or where the myocardial dysfunction was thought to be due to septicemia with septic shock. 
We identified cases through the admission/discharge diagnoses using the International Statistical Classification of 
Diseases codes (ICD10 codes), reviewing ECHO request records  and manually reviewing the “Causes of deaths 
register”. Data were collected from the paper and electronic notes made by doctors, cardiology outpatient records and 
autopsy reports. Demographic, clinical, laboratory, ECHO, ECG and CXR data were collected on case report forms. Viral 
myocarditis, for the purposes of this study was a case where a significant virus, known to be associated with myocarditis, 
was isolated on either PCR of tracheal aspirate (TA)/nasopharyngeal aspirate (NPA), urine or on blood test. In children 
where cytomegalovirus was found on any specimens we considered it a significant infection only if the blood viral load 
was shown to be more than 1000 copies/ml (Log 3). The metabolic, autoimmune screens and ECGs in these cases were 
normal. Statistical analysis was performed with StataCorp. 2015. Stata Statistical Software: Release 14. Standard 
descriptive analysis, including measures of central tendency and dispersion, was performed for measured variables while 
frequencies and proportions were described for categorical variables. For comparisons based on mortality, chi-squared 
test (or exact tests for sparse data) and t-and rank sums for parametric and non-parametric data were used. Analysis of 
survival/mortality used time to event methods including Kaplan-Meier graphs. For patients lost to follow up, survival was 
censored at the last known date to be alive. For all hypothesis tests a significance level of 0.05 was used while the 95% 
confidence intervals (CI) were reported were necessary.  
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Results: We identified 227 potential cases within the broad diagnoses groups of myocarditis, dilated cardiomyopathy, 
myocardial dysfunction etc. Based on the inclusion and exclusion criteria stated in the methods 117 cases were included. 
Nineteen children were diagnosed at postmortem only. The median overall age at presentation was 18.9 months 
(Interquartile range (IQR) 8.9-52.2), with the children diagnosed at post mortem only slightly younger with a median of 
10.6 months (IQR 2.2-28.8). Ninety-five percent (n=94/99) were in cardiac failure at presentation and 85.7% (n=90/105) 
were noted to have cardiovascular instability. Admission left ventricular ejection fraction was less than 30% in 68.2% 
(n=60/88). Eighty out of 117 (68.4%) children survived the first admission till hospital discharge and 65/117 (55.6%) 
children where noted to be alive at the end of the review period. On multivariate analysis the only factors that predicted 
death where renal dysfunction and cardiac failure at presentation. Thirty-three of 117 (28.2%) children had a short history 
of symptoms of less than 3 days. CXR at presentation was always abnormal and of the 97 CXR reviewed 90 (92.8%) had 
an increase in the cardiothoracic ratio. Seventy of 108 cases (64.8%) for which data was clear required pediatric intensive 
care admission; with the median length of ICU being 7 days (IQR 4-11 days). Forty-six of 107 (43%) children required 
ventilation for a median of 4 days (IQR 1-5) and 70/101 (69.3%) required inotropic support with 59/94 (62.8%) receiving 
dopamine and/ or dobutamine, 23/89 (25.8%) adrenaline infusions and 22/88 (25.0%) received milrinone. The overall 
duration of initial admission was 10 days (IQR 3-18), 5 days (IQR 1-15) for children who died and 12 days (8-20) for 
those who survived. Complications during hospitalization included acute kidney injury in 82/108 (75.9%) (3 needed 
dialysis), liver enzyme derangement in 69/81 (85.2%). Fourteen of the 91 children who had blood cultures taken (15.4%) 
at the time of admission had positive cultures, with 7/14 (50.0%) only diagnosed at postmortem. Aetiology 
was presumed to be viral myocarditis in 54/117 (36.7%) of the children. In 34/117 (29.1%) of cases, either their 
investigations/work-up was not complete hence classified as “not determined” or their full screen (excluding genetic 
testing) was negative hence “idiopathic” classification. Viral studies were positive in 73 (76.8%) of the 95 children where 
specimens were sent however not all cases with positive viruses where classified as having viral myocarditis, it depended 
on the virus isolated and other factors. Parvovirus PCR was positive in 17/41 (41.5%), significant CMV viral load in 
16/40 (40%), Adenovirus in 5/69 (7.2%) and enteroviruses in 6/69 (8.7%). Two or more viruses where found in 37/95 
(38.9%) patients. Twenty-four of the 117 (20.5%) children were known to be HIV exposed and of these 7 (29.2%) were 
HIV infected. 4 of the HIV infected children died, 5 (71.4%) dying within 7 days of diagnosis. The median duration of 
follow up time from first diagnosis was 474 days (IQR 147-820). 62 of the 80 first admission survivors attended cardiac 
OPD. Fourteen of the 62 children (22.6%) recovered fully and were discharged from the service, and in total 38 of the 62 
clinic attenders (61.3%) were noted at a point with a normalized EF. Twenty-four of the 80 initial survivors (30%) were 
lost to follow-up. The median EF at the latest ECHO was 53% (IQR 35%-59%). The change in EF from diagnosis to 
latest ECHO was a median increase of 22.5% (IQR 9%-34%). 
Conclusions 
This study confirms that myocarditis and DCMO are an important cause of cardiac morbidity and mortality in South 
African. This study emphasises the need for a high index of suspicion of myocarditis and rapid PICU access to improve 
mortality. Bacterial infections are important contributors to death in this cohort and must be considered. Although we 
may be underestimating the total deaths in this cohort the survival after the first admission was good and supports the 


























Inleiding: Ongeveer 27% van nuwe gevalle van hartversaking in kinders van hulpbron-ryke lande is die gevolg van siektes 
van die miokardium. Dit is dikwels nie moontlik om akute miokarditis en gedilateerde kardiomiopatie (DCMO) klinies van 
mekaar te onderskei nie, tog is dit unieke siekte entiteite. Miokarditis en DCMO het verskeie oorsake, maar virale infeksie 
is die algeenste oorsaak van miokarditis, en virale miokarditis is die algemeenste oorsaak van DCMO 
Die oorsaak mag onbekend bly, veral wanneer gevalle nie deeglik ondersoek word nie. Entero-en adenoviruse is steeds 
belangrike oorsake van miokarditis maar mettertyd het die rol van parovirus B19 en herpes virusses al hoe duideliker 
geword. 
Toenemende ontwikkeling van genetiese en metaboliese evaluering het ook tot ‘n vermindering van die getal idiopatiese 
gevalle gelei. Die kliniese simptome van miokarditis en DCMO sluit die volle spektrum van asimptomaties, tot skielike 
hartversaking of dood in. Pasiente word dikwels inisieel foutiewelik met respiratoriese siekte gediagnoseer. Kinders met 
DCMO is gewoonlik uiters siek by diagnose, met hartversaking wat in 90%-100% van gevalle teenwoordig is. 
Diagnostiese toetse word gebruik om die diagnose van miokardiale disfunksie  te maak en om die oorsaak te indentifiseer. 
Borskas radiografie (CXR) en elektrokardiogramme (EKG) word dikwels gebruik as voorlopige ondersoeke en is in meer 
as 90% van gevalle abnormaal. ECHO-ondersoeke word gebruik om die diagnose te maak, om strukturele en ander oorsake 
van hartversaking uit te skakel en ‘n basislyn te bepaal. Polimerase kettingreaksie (PCR) kan virale genome in verskeie 
weefsels identifiseer – PCR identifikasie van viruse op respiratoriese monsters korreleer sterk met virale infeksie in die 
miokardium. Terapie is gefokus op die behandeling van volume oorlading and swak perfusie. Toegang tot ventilatoriese 
ondersteuning, ekstrakorporeale membraan-oksigenasie (ECMO), ventrikulêre ondersteunings toestelle (VAD) en 
hartoorplantings het drastiese gevolge gehad vir die uitkomstes en resultate in hulpbronryke lande. Kinders wat in 
hulpbronryke lande gehospitaliseer word het ‘n oorlewingsyfer van 94% teen 1 jaar en 89% teen 5 jaar. Die risikofaktore en 
voorspellers vir dood is ouderdom (neonatale periode en ouer kinders), hartversaking, laer verkortingsfraksie (SF<15%) en 
uitwerpfraksie (EF <30%), en etiologie van DCMO. Byna alle data van die uitkomstes van kinders met – of wat 
behandeling ontvang vir – akute miokarditis en DCMO word kom van ontwikkelde lande met gesofistikeerde mediese 
dienste en intervensies. Daar is min data wat die kliniese uitbeelding, uitkomstes en oorsake van miokarditis en DCMO in 
kinders in middel- tot lae hulpbron instellings beskryf. Die enigste studie vanuit Suid-Afrika rapporteer die aanvanklike 
hospitaal-oorlewing as 47% van kinders in die pediatriese intensiewe sorgeenheid (PICU), met geen data oor langtermyn 
uitkomstes nie.  
Doelstellings en Doelwitte: Die doel van hierdie studie is om die kliniese uitbeelding, koers en uitkomste – insluitend 
siektekoers en sterftekoers van kinders met miokarditis en DCMO – te ondersoek en te probeer om vas te stel watter faktore 
n swak uitkoms voorspel. Die resultate hoop om plaaslike klinici te lei in die ontwikkeling van riglyne vir kinders, hulp met 
voorspelling van siektes, en potensieel te help om areas te identifiseer waar die bestuur en die gebruik van skaarse 
hulpbronne verbeter kan word.  
Metodes: Ons het gebruik gemaak van ‘n retrospektiewe, beskrywende studie in kinders vanaf geboorte tot 13 jaar, 
gediagnoseer met akute miokarditis en DCMO, vanaf 1 Januarie 2008 tot 31 Desember 2015 by Tygerberg Hospitaal – ‘n 
tersiêre sorg hospitaal in die Wes Kaap, Suid-Afrika. Insluitings-kriteria was die diagnose van miokarditis of DCMO, 
gebasseer op ECHO bevindinge of ‘n EF <55% en/of ‘n SF <25%, of antemortem of postmortem histologie. Kinders was 
uitgesluit indien daar strukturele of vaskulêre abnormaliteite van die hart was, of waar die miokardiale disfunksie 
toegeskryf was aan septisemie met kompliserende septiese skok. Ons het gevalle geïdentifiseer deur die opneem/ontslag 
diagnoses, die “International Statistical Classification of Diseases” kodes (ICD10), en deur handmatig die doodsoorsaak-
register) te ondersoek. Die kardiologie-buitepasiënt rekords en nadoodse-ondersoek verslae was ook nagegaan en papier en 
digitale doktersnotas. Demografiese, kliniese, laboratorium, ECHO, EKG en CXR data was ingesamel op verslagvorms. 
Virale miokarditis was, vir die doel van hierdie studie, ‘n geval waar ‘n betekenisvolle virus, geassosieer met miokarditis, 
geïsoleer was op of PCR of trageale aspirasie/nasofaryngeale aspiraat, urine of bloed toetse. In kinders met sitomegalovirus 
op ‘n respiratoriese of urine monster het ons dit slegs as ‘n ernstige infeksie klassifiseer indien die virale vlak in die bloed 
bewys was om meer as 1 000 kopieë/ml (Log 3) te wees. Die metaboliese, outoimmuunsiftings en EKGs was in hierdie 
gevalle normaal. Statistiese analise was uitgevoer met StataCorp. 2015. Stata Statistical Software: Release 14. Standaard 
beskrywende analise, insluitend mates van sentrale neiging en verspreiding, was uitgevoer op gemete veranderlikes, terwyl 
herhalings en verhoudings beskryf was vir kategoriese veranderlikes. In gevalle van vergelykings gebasseer op mortaliteit, 
was chi-squared toetsing (of presiese toetse vir skaars data), en T- en rang berekeninge vir parametriese en nie-parametriese 
data gebruik. Vir die analise van oorlewing/sterflikheid was gebruik gemaak van verskeie metodes, insluitend Kaplan-
Meier beramings. In die gevalle waar pasiënte verlore gegaan het vir opvolg-ondersoeke, was oorlewing gesensuur teen die 
laaste bekende datum van oorlewing. Vir alle hipotetiewse toetse was ‘n betekenispeil van 0.05 gebruik, terwyl die 95% CI 
soos nodig gerapporteer was. 
Resultate: Ons het 227 potensiële gevalle identifiseer, waarvan 117 ingesluit was. Negentien kinders was slegs met 
postmortem gediagnoseer. Die mediaan-ouderdom teen die tyd van presentering was 18.9 maande (IQR 8.9-55.2), met die 
kinders gediagnoseer tydens postmortem slegs effens jonger, met ‘n mediaan van 10.6 maande (IQR 2.2-28.8). Vyf en 
negentig present (n=94/99) was in hartversaking tydens presentering en 85.7% (n=90/105) gediagnoseer met 
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kardiovaskulêre onstabiliteit. Toelating ventrikulêre ejeksie was minder as 30% in 68.2% (n=60/88). Tagtig uit 117 
(68.4%) kinders het hospitaal ontslaning oorleef op diagnosis toelating en die totale oorlewingssyfer was 65/117 (55.6%). 
Volgens meerveranderlike studie is nier- en hartversaking tydens presentasie die enigste voorspellers vir dood. Drie en 
dertig uit 117 (28.2%) kinders het ‘n kort geskiedenis van simptome gehad, oor ‘n tydperk van minder as drie dae. CXR by 
presentasie was altyd abnormaal en, van die 97 CXR wat bestudeer is, het 90 (92.8%) ‘n toename in kardiotorakale ratio 
getoon. Seventig van 108 (64.8%) van die pasiënte het pediatriese intensiewe sorg toelating benodig, met die mediaan 
PICU verblyf op 7 dae (IQR 4-11 dae). Ses en veertig van 107 (43%) kinders het ventilasie benodig vir ‘n mediaan van 4 
dae (IQR 1-5) en 70/101 (69.3%) het inotropiese ondersteuning benodig, terwyl 59/94 (62.8%) dopamien en/of dobutamien 
ontvang, 23/89 (25.8%) ontvang adrenalien infusie, en 22/88 (25.0%) ontvang milrinone. Die algehele voortduring van 
aanvanklike toelating was 10 dae (IQR 3-18), 5 dae (IQR 1-15) vir dié kinders wat gesterf het en 12 dae (8-20) vir dié wat 
oorleef het. 
Komplikasies gedurende hospitalisering sluit in akute nierbesering in 82/108 (75.9%) kinders waarvan 3 pasiënte dialise 
benodig, lewer-ensiem versteuring in 69/81 (85.2%) en bakteriële sepsis. Veertien van die 91 kinders (15.4%) wat bloed 
kulture geneem het, het positiewe bloed kulture tydens opname, met sewe uit viertien (50.0%) hiervan wat eers tydens 
postmortem gediagnoseer word. Etiologie was aanvaar as virale miokarditis in 54/117 (36.7%) van die kinders. In 34/117 
(29.4%) van gevalle was die ondersoeke of onvoltooid en dus geklassifiseer as “nie-vasgestel”, óf die volle toetse 
(uitsluitend genetiese toetsing) was negatief, dus die “idiopatiese” klassifisering. Virale studies was positief in 73 (76.8%) 
van die 95 kinders wie se monsters gestuur en ondersoek was. Parovirus PCR was positief in 17/41 (41.5%), beduidende 
CMV virale las in 16/40 (40%), Adenovirus in 5/69 (7.2%) en enteroviruse in 6/69 (8.7%). Twee of meer viruse is by 37/95  
(38.9%) van die pasiënte gevind. Vier en twintig van 117 (20.5%) van die kinders was blootgestel aan MIV en, van die, 
was 7 (29.2%) geïnfekteer met MIV. Vier van die MIV-geïnfekteerde kinders het gesterf, 5 (71.4%) binne die eerste sewe 
dae na diagnose.  
Die mediaan-duur van opvolg-tyd vanaf die eerste diagnose was 474 dae (IQR 147-820). Twee en sestig van 80 eerste 
opname oorlewendes her hartpatiente bygewoon. Veertien van die twee en sestig kinders (20.3%) het herstel en was 
onstlaan vanuit die harteenheid, in 38/62 kinders (61.3%) het EF genormaliseer. Vier en twintig van die tagtig aanvanklike 
oorlewendes (34.7%) was verlore vir opvolgondersoeke. Die mediaan EF tydens die mees onlangse ECHO was 53% (IQR 
35%-59%). Die verandering in EF vanaf diagnose tot die laaste ECHO was ‘n mediaan toename van 22.5% (IQR 9%-
34%). 
Gevolgtrekkinge: Binne ons raamwerk en instellings is akute miokarditis en DCMO geassosieer met opmerklike 
morbiditeit en mortaliteit. Hierdie studie benadruk die behoefte na ‘n hoër indeks van agterdog van miokarditis en 
versnelde toelating tot PICU om sodoende oorlewing te verbeter. Bakteriële infeksies is belangrike bydraers tot dood in 
hierdie kohort en moet dus oorweeg word. Alhoewel ons moontlik die totale dodetal binne die kohort onderskat, was die 
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Introduction/Literature review  
 
Apart from congenital structural heart disease, cardiac failure in children has many causes. Approximately 27% of 
new cases of paediatric cardiac failure in the United States are due to abnormalities of the myocardium. Acute 
myocarditis and dilated cardiomyopathy (DCMO) may be clinically indistinguishable at presentation but are distinct 
diseases. Acute myocarditis results in DCMO in 21-30% of cases and is an important cause of DCMO in children. 
(2,3)  
In 1995 the World Health Organization (WHO) and International Society and Federation of Cardiology (ISFC) 
established a histopathological case definition for myocarditis, the Dallas criteria. For the diagnosis to be made, an 
endomyocardial biopsy (EMB) must be performed and specific immunological and immunohistochemical criteria 
should be met. (4,5,6,7,8) EMB remains the gold standard for the diagnosis of myocarditis, but in many high and low 
resource settings, the diagnosis is made by a combination of clinical findings, echocardiography (ECHO) and 
increasingly magnetic resonance imaging (MRI), where it is available. (3,4,5,6,7,8) 
Cardiomyopathies are broadly defined as "diseases of the myocardium associated with cardiac dysfunction". (9) The 
cardiomyopathies are then subdivided by the anatomical and physiological anomalies. The causes of DCMO include 
myocarditis and a broad range of genetic and acquired disorders that manifest as a spectrum of electrical and 
functional abnormalities. The clinical phenotype is that of ventricular dysfunction with chamber enlargement.  
 
For the purposes of this study, myocarditis and DCMO were studied as a single entity due to various complexities in 
separating these entities clearly and the continutuum/overlap that often pursues. 
Incidence of myocarditis and dilated cardiomyopathies  
The initial diagnosis of myocarditis is highly dependent upon clinical suspicion. Early acute myocardial dysfunction 
may be missed, and the diagnosis of myocarditis may only be obvious when fulminant disease is present, or when 
considered in retrospect, when the child presents with DCMO. (10) Using screening electrocardiograms (ECG), the 
approximate incidence of myocarditis is estimated to be 7 per 60 000 (0.012%) in asymptomatic Japanese children. 
(8) This incidence increases to between 0.15% and 0.6% of the population when using postmortem data. (8) The 
prevalence in a Canadian paediatric emergency department was estimated to be 0.5 cases per 10 000 emergency 
department visits. (11) There are no data on the incidence or prevalence in South African children. 
The incidence of DCMO in developed countries is between 0.57 and 1.3 cases per 100 000 children aged 1-18 years. 
(12) Infants have the highest incidence in the paediatric age group, ranging between 4.1 and 8.34 per 100 000. (13,14) 
The incidence is higher in boys than in girls, and higher in Africans than in Caucasians. Similar to myocarditis there 
are no data on the DCMO incidence in South African children. 
Causes of myocarditis and dilated cardiomyopathies 
Although there are a number of infections and conditions that can cause myocarditis, the cause often remains obscure, 
particularly if cases are not rigorously investigated. Viral infections are the most important cause. (5,6,8,15,16,17) In 
viral myocarditis the initial viral infection is often accompanied by a prodrome of respiratory and gastrointestinal 
symptoms and during this phase direct myocyte injury can occur. This is followed by injury caused by the T cell and 
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cytokine activation of the host immune response. In a subset of survivors, long-term dysfunction results in DCMO, 
and it is not clear why this happens in some but not all cases. Current suggestions include specific immunogenetics 
allowing for long-term autoimmune and inflammatory damage. (6,15) Enteroviruses including Coxsackie group B, 
adenovirus, parvovirus B19, and human herpes 6 (HHV-6) have been noted to be important aetiological agents. 
(8,17,18,19,20,21) A shift in causes has been noted over time, and although entero- and adenoviruses remain 
important, parvovirus B19 and herpes virus are increasingly recognized as common causes. (21,22,23) Studies of the 
causes of viral myocarditis are summarized in Appendix 1: A table summarizing studies from 1999-2016 in which 
viruses were isolated in cases of myocarditis.  
 
There are few local data sources; in a recent report of children presenting in heart failure to the Paediatric Intensive 
Care Unit (PICU) of Red Cross War Memorial Children’s Hospital (RCWMCH) in Cape Town, the aetiology was 
presumed viral myocarditis in (83/95) 87% and idiopathic DCMO in (13/95) 13%. (24) Adenovirus PCR was positive 
in 28/95, Parvovirus in 19 with multiple positive viral studies in 32/95. (24) Myocarditis can also be caused by non-
viral infections, medication, toxins and hypersensitivity (eosinophilic myocarditis). (4) Other causes include 
arrhythmias, metabolic diseases, autoimmune and inflammatory conditions. 
 
Forty-eight to 60% of DCMO cases in children are idiopathic; the remaining cases are secondary to viral myocarditis 
(22.3%), familial disease (14.7%), metabolic disease (4-11%), neuromuscular disease and cardiotoxic drugs. (22,25) 
As genetic screening and metabolic evaluations are becoming increasingly sophisticated, the numbers of idiopathic 
cases is becoming smaller. Myocardial dysfunction due to myocarditis and DCMO, with or without cardiac failure is a 
well-known complication of human immune deficiency virus infection. (4,26,27) Pulmonary disease and infections 
and HIV itself, can trigger the cardiac failure in these children, with both systolic and diastolic dysfunction being well 
described. (28) 
Clinical Presentation 
The clinical presentations of myocarditis can range from asymptomatic to fulminant cardiac failure, life threatening 
arrhythmias or sudden death. (4,5,7,8,10,15,17,29) Between these extremes, patients have non-specific systemic 
symptoms of fever, upper respiratory symptoms, cough, fatigue and gastrointestinal symptoms such as nausea, poor 
feeding and vomiting. (6) There is a large variability in the presentations of different age groups, with infants 
presenting with tachypnoea, poor feeding and failure to thrive and older children with chest pain, palpitations, effort 
intolerance and syncope. (5,15) In a study of 90 patients younger than 16 years who died suddenly and unexpectedly, 
myocarditis was found to be a major cause of death in 17%, and of these, 60% had prodromal symptoms. (10) 
Symptoms may not be recognized initially as myocarditis, and 57%- 84% of patients required more than one visit to a 
physician within 14 days before the diagnosis was made. (8,10) Children are often initially diagnosed with respiratory 
illness. (8,10) 
Children with DCMO are usually very ill at the time of initial assessment, with cardiac failure being present in 90%-
100% of patients. (22,24,25) A population-based cohort study of all children in Australia who presented with 
cardiomyopathy at age 0 to 10 years over a 10-year period showed hospitalization on initial presentation is common 
(88%) and of the children that require hospitalization, 45.1% needed intensive care admission on initial presentation. 
(30) The majority of patients with DCMO require inotropic medication and nearly half endotracheal intubation and 
assisted ventilation. (30)  
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Diagnosis   
Diagnostic tests are directed towards confirming the diagnosis of myocardial dysfunction and identifying the cause. 
Chest radiograph (CXR) is abnormal in 90% of cases (10) with findings consistent with cardiac failure in the form of 
cardiomegaly (60%) and increased pulmonary markings suggestive of pulmonary oedema. (10,15) Cardiomegaly on 
paediatric CXR is highly predictive of ventricular dilatation on ECHO. (12)  
Electrocardiogram (ECG), despite its low sensitivity and specificity, is widely used as a screening tool and is 
frequently abnormal in between 93% and 100% of cases with myocardial dysfunction. (4,5,8,10,12) The typical ECG 
has sinus tachycardia with low-voltage QRS complexes, but beyond this, there are a variety of abnormalities including 
ST and T wave abnormalities, widened QRS complexes, axis deviation, and arrhythmias. (4,6,8,12,15) 
ECHO examination is used to confirm the diagnosis, exclude structural and other causes of cardiac failure and to 
establish a baseline for monitoring and follow-up. (4,5,12,23) The examination looks at the measurement of ejection 
fraction (EF) and shortening fraction (SF), the presence or absence of atrioventricular valve regurgitation, as well as 
the presence of pericardial or pleural effusion and intraventricular thrombi. (12,15) An EF of less than 55% and/or a 
SF of less than 25% are commonly used as criteria to diagnose left ventricular systolic dysfunction. (12,22) 
Non-specific laboratory studies include general markers of inflammation and infection, such as a full blood count, a 
differential count, a serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). (4,15) These markers 
may be elevated in cases of acute myocarditis but normal values do not exclude an acute myocardial inflammatory 
process. (4) Lactate, acid base, hepatic enzymes tests and creatinine are useful to assess perfusion. (15)  
Cardiac troponins T and I and creatine kinase (CK), which are markers of cardiac injury, may assist with the diagnosis 
of myocarditis, but there are limited data on their use in children. (4,5,6,8) In patients with clinically suspected 
myocarditis, troponins are more sensitive than CK levels as markers of cardiomyocyte injury, but normal serum levels 
do not exclude myocarditis. (5) Cardiac troponin T may provide better sensitivity for detecting micro-necrosis 
because of a proportionally higher and longer lasting elevation of serum levels. (8) Troponin I has high specificity but 
limited sensitivity in the diagnosis of myocarditis, whereas cardiac troponin T has been reported to have a sensitivity 
of 71%. (15)  
In the absence of EMB, the diagnosis of viral myocarditis relies on the identification of virus by molecular techniques, 
culture for peripheral specimens, and serial serology. (19) A 4-fold rise in acute antibody titers is necessary to assign 
causality to a specific virus. (6) Polymerase chain reaction (PCR) can detect viral genomes in many tissues including 
nasal pharyngeal aspirates (NPA), tracheal aspirates (TA), stool, urine and myocardial biopsy samples. (6,26) The 
identification of viruses on respiratory specimens with PCR correlates well with those obtained from the myocardium, 
hence the widespread use of this method to identify potential viral causes. (30,31) Detection of a viral genome does 
not necessarily indicate causality however, as for instance, cytomegalovirus may shed due to disease, and the presence 
of respiratory viruses in the upper airways may occur in asymptomatic children. (32) 
EMB however, remains the gold standard of diagnosis, with histology complemented by sensitive histochemical and 
molecular methods. (23) Histology provides crucial information regarding the type of inflammatory infiltrates such as 
lymphocytes, neutrophils, eosinophils, granulomas or giant cells. (23) EMB is not routine in South Africa and even in 
high-income settings it is thought that the risks may outweigh the benefit. If EMB should be performed, the Dallas 
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“histopathologic” criteria, developed to improve diagnostic capabilities and decrease the high rate of diagnostic 
disagreement by establishing uniform criteria, should be used. (19)  
Cardiac MRI provides detailed functional and morphological assessment of the heart, as well as reliable visualization 
of tissue markers of myocarditis, including oedema, inflammation and fibrosis. (8) To standardize cardiac MRI in 
diagnosing myocarditis, the International Consensus Group on Cardiovascular Magnetic Resonance created the “Lake 
Louise Criteria”.  (8) Two out of the following three criteria are required to fulfill the diagnosis of myocarditis: 
1. On T2 scan a myocardium to skeletal muscle ratio > 1.9 
2. Delayed enhancement in subepicardial and or mid-myocardium in nonischemic distribution 
3.  Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal 
muscle in gadolinium-enhanced T1weighted images. 
Not only is MRI a non-invasive adjunct in diagnosing myocarditis, but it is also useful in the monitoring of disease 
progression. More data are needed in children. (2,5,8,12,15) Nuclear imaging with gallium-67, Tl-201 and indium-
111-labeled anti- myosin antibodies (5,6) can also be used in the myocarditis diagnosis. Cardiac catheterisation is part 
of the pre-transplant work-up, diagnostic biopsy or of left atrial decompression after extracorporeal membrane 
oxygenation (ECMO) cannulation. (25)  
Management 
The approach to therapy for patients with myocarditis and DCMO remains supportive care. (4) Medical therapy in 
children with myocarditis and DCMO is less effective than in adults. Whilst mortality and the requirement for 
eventual cardiac transplantation may be reduced by aggressive use of medical therapies, such as ACE-inhibitors in 
children, their impact in the youngest of patients has yet to be defined. (30) The long-term limitations of 
transplantation, and the lack of sufficient young donors justify the continuing search for better medical therapy. (30)  
Initial management is focused on fluid overload, under perfusion or both. (12) Stabilization includes access to 
ventilatory support and intravenous inotropic support, extracorporeal membrane oxygenation (ECMO), ventricular 
assist devices (VAD) and cardiac transplantation. In children with decompensated cardiac failure who have evidence 
of low cardiac output, poor perfusion and shock; inotropes, including dopamine, dobutamine and milrinone are used 
to improve the end organ perfusion. (12) There are no clinical studies to guide inotropic use, however milrinone is 
currently the preferred inotrope because of its afterload reduction. (8)  
Loop diuretics, such as furosemide, play a key role in the active management of patients with symptomatic cardiac 
failure. (12) In advanced cardiac failure, angiotensin-converting enzyme inhibitor (ACE-I) therapy is usually 
introduced after the stabilization of heart failure symptoms with a diuretic, and simultaneous to withdrawal of 
inotropic support. Captopril is typically first choice for most children. (12) ACE- inhibitors may also help to prevent 
the remodeling that evolves in DCMO. (8) Data regarding the role of aldosterone antagonist therapy such as 
spironolactone in the treatment of children with cardiac failure are very limited. (12) Spirinolactone is typically 
initiated in children in whom therapy with an ACE-inhibitor has not resulted in improved ventricular function or 
reversal of ventricular remodeling. (8,12)  
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Preventative anticoagulation may be considered if the EF is severely decreased, in atrial arrhythmias and as therapy in 
patients with intraventricular thrombi. (8) Systemic anticoagulation was administered in 24/175 (13.7%) of Daubeney 
et al’s patients. (30)  
 
An area of significant controversy involves the use of immune modulators in the context of myocarditis. (8,15) More 
than 20 treatment trials performed in adults have been reported using immunosuppressive, immune modulating or 
anti-inflammatory drugs. (4) It is difficult however to extrapolate the findings of adult studies to the paediatric 
population. Paediatric studies of agents such as prednisone, azathioprine and cyclosporine are rare and inconclusive. 
(6,8) A small randomized controlled trial, comparing 3 different immunosuppressive treatment strategies, failed to 
show any haemodynamic or clinical improvement with steroid use. A recent Cochrane review does not support the 
use of corticosteroids in the treatment of myocarditis. (12) Intravenous immunoglobulin (IVIG) is the most commonly 
used immune modulator in myocarditis. (30) Despite several reports that suggest improved outcome in children who 
received IVIG, a review of a large number of registry patients from Canada showed no improvement in outcome. 
Many patients with myocarditis have spontaneous improvement. It is therefore difficult to know if the observed 
improvement after treatment with immunosuppression or IVIG is attributable to treatment or the natural course of the 
disease. (8)  
The rationale for the use of antiviral drugs results from the knowledge that most common causes of myocarditis are 
induced by viral infections. (4) Acyclovir and ganciclovir may be considered in patients with herpes virus or 
cytomegalovirus infections and as newer agents become available these will need to be considered as therapeutic 
agents. (4,5,33) 
Mechanical support devices and ECMO are other treatment or management modalities. Mechanical support devices 
have been said to be life saving in 67% of patients, especially those with acute fulminant myocarditis (AFM). (6) For 
patients with cardiogenic shock due to AFM who deteriorate despite optimal medical therapy, VAD or ECMO might 
be required for the aggressive short-term treatment of refractory cardiogenic shock, to bridge the patient to recovery or 
heart transplantation. (4)  
Early data suggest that a third of children die or undergo transplantation within 1 year of presentation. (34) The 
improvement in survival with paediatric cardiac failure in the United Kingdom (UK), Ireland and the United States 
(US) does appear to be related to an earlier and more aggressive recourse to transplantation. (34)  
Short and long-term outcomes 
Myocarditis and DCMO, with or without cardiac failure, have substantial morbidity and mortality. (35,36) Overall 
survival rates in children with myocarditis or DCMO have varied in the literature and depend on the aetiology, clinical 
presentation, disease stage, access to care and management. (4,5) Survival should be distinguished from full recovery. 
There is an ongoing debate about the extent to which outcomes of heart failure from heart muscle disease in children 
have improved over the years. (37) An entire generation of paediatric cardiologists in the UK and internationally was 
taught that in children with myocardial disease, a third (33%) die, a third develop chronic impairment, and a third get 
better. (6,36) This originated from Greenwood's 1976 study of 161 children. (38) Kantor reports that 66% of patients 
recover, 10% show incomplete recovery and 24% progress to death or transplantation. (12) A large, multi-centered 
study including all age groups showed that there was a significant mortality in neonates (33-45% survival) (8) with 
older infants and young children having better outcomes (78-80% survival). AFM may have a better prognosis. (39) 
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Patients are more likely to experience complete recovery of left ventricular function, if aggressive pharmacological, 
mechanical and ventilatory supports are initiated early. (4,7,25) Therefore, despite an increased likelihood of death 
early in their illness trajectory, patients with an acute fulminant presentation should be managed aggressively. (39)  
 
Apart from age at initial presentation, poor outcome from acute myocarditis has been shown to be more likely in 
patients with elevated CRP, elevated CK, EF <30%, and intraventricular conduction disturbances. (6) There is no 
difference in the outcomes of children with biopsy confirmed versus probable myocarditis. (26) Myocarditis may 
account for nearly half of all children with DCMO and 1-8% of patients with acute myocarditis eventually go on to 
transplant. (8)  
 
It is essential to try and establish the aetiology of DCMO in order to determine the subsequent optimal management 
and gauge accurate prognosis. The overall prognosis of idiopathic forms of DCMO tends to be poor with a reported 5-
year mortality rate in the literature of 14-50%. (22) DCMO secondary to viral myocarditis has substantially better 
outcomes. (2,6) The Australian Childhood Cardiomyopathy Study and the American Pediatric Cardiomyopathy 
Registry provided valuable data about longer‐ term outcomes for specific diagnostic groups. (40,41) The most recent 
overall survival rates in North America, from a large population cohort, are a 1-year survival of 87% and 5-year 
survival of 77%. (13) 
 
 
Similarly Andrews has recently shown that children who survive an initial hospitalization with heart failure from heart 
muscle disease have a good medium‐ term survival (82% overall 1‐year survival but 77% at 5 years and 73% at 
10 years, with survival conditional on 1‐year survival 94% & 89% at 5 and 10 years respectively). (36) This cohort 
differs from the US and Australian cohorts in that it was selected to look at outcomes of symptomatic new‐onset 
clinically significant heart failure in children, rather than cardiomyopathy per se. The predictors of outcome were 
similar. (36) These predictors and risk factors for death of DCMO are age (neonatal period and older age at 
presentation, sparing the group of infants and toddlers), congestive cardiac failure, lower SF (<15%) and EF (<30%) 
as well as idiopathic DCMO. (8,13,17,22,25,37,40,42,43,44) Patients with cardiac failure at presentation were 4 times 
more likely to experience death or transplantation within 1 year of diagnosis. (25)  
The only study from South Africa reports an initial hospital survival of 47% for children admitted to PICU. (24) There 












Stellenbosch University  https://scholar.sun.ac.za
15 
 
Research justification  
 
Although there is a large body of evidence on the outcomes of infants and children presenting with and treated for 
acute myocarditis and DCMO, nearly all of this data are reported from developed countries with sophisticated medical 
services and interventions, such as ventricular assist pumps and cardiac transplantation. These reports may have 
limited applicability to children who live in countries where predominantly the population income is middle to low, or 
where the causes of myocardial failure may differ, or where access to health care is a challenge and often delayed. 
Middle and low-income countries, as well, are burdened by complicating infectious diseases including tuberculosis 
and HIV infection and disease.  
 
At Tygerberg Hospital, children have access to a specialized cardiology service, and limited access to paediatric 
intensive care and high care. Children are diagnosed with myocarditis and DCMO through history, clinical assessment 
and ECHO. This study creates the opportunity to investigate these infants and children collectively in order to 
determine which factors predict a poor outcome. The results of such a study would support clinicians to develop 
guidelines for infants with acute myocarditis and DCMO.  
 
Local data on the outcomes of the children will assist with prognostication and potentially identify areas where 
management and the utilization of scarce resources can be improved. 
 
Aims and Objectives 
 
The aim of this study is to investigate the clinical presentation, course and outcome; including morbidity and mortality 
of children with myocarditis and DCMO presenting to Tygerberg Hospital, and to attempt to determine the factors 





This study was performed in Tygerberg Hospital, a tertiary care hospital in the Western Cape, South Africa; which is 
a referral hospital for parts of the Cape Town Metropolitan and two health regions of the Western Cape. The reference 
population is approximately 2 million persons of which 35% are children. The region has a high prevalence of 
tuberculosis and HIV, with the Western Cape currently having the fourth highest TB incidence rate in South Africa 
(739.1 per 100 000 population). (45) A 2011 estimate of TB prevalence in Cape Town is 511/100 000 in children 
under 5 years of age. (46) The HIV prevalence in 2012 was reported as 2.4% in children aged between 0-14 years. 
(47) The paediatric cardiology service has qualified paediatric cardiologists with access to ECHO and other highly 
technical investigations. There are a limited number of PICU and high care beds resulting in competition for access to 











Period of study, study population and eligibility criteria 
 
A retrospective descriptive study of all children from birth to 13 years (age limit due to paediatric admission criteria) 
diagnosed with acute myocarditis or DCMO presenting to TBH from 1 January 2008- 31 December 2015, was 
performed. 
 
We identified potential cases through an extensive search of the admission and discharge diagnoses of patients 
admitted to all paediatric services. The patients with myocarditis and DCMO were identified using the 10th revision 
of the International Statistical Classification of Diseases and Related Health Problems codes (ICD10 codes) 
(Appendix 2), to search through the hospital electronic systems. The “Causes of deaths register” kept as part of the 
National CHIP programme was also manually reviewed. The laboratory, ECHO and cardiology service records as 
well as cardiology outpatient records and autopsy reports were also reviewed.  
 
A case of myocarditis or DCMO (for study purposes included as as a single entity due to the difficulty in clinically 
distinguishing these entities) was defined as a child younger than 13 years of age at diagnosis, with myocardial 
dysfunction as determined by an ECHO with an EF of less than 55% and/or a SF of less than 25%. Children in whom 
the diagnosis was made at postmortem, through histology, were also included. Children were excluded if there were 
structural or vascular abnormalities of the heart, or where the myocardial dysfunction was thought to be due to 
septicemia with complicating septic shock.  
 
Data Collection  
 
Paper and electronic notes made by doctors were reviewed for both the inpatient and outpatient services.  A registered 
paediatric cardiologist reviewed all ECHOs and ECGs. CXRs were reviewed by a paediatric pulmonologist. 
Demographic, clinical, laboratory, ECHO, ECG and CXR data were collected on case report forms (Appendix 3) and 
transcribed to an Excel spread sheet (Microsoft). 
 
NHLS (National Health Laboratory System) was reviewed for all investigation results, based on the available 
departmental guidelines. These guidelines exist to assist clinicians in the investigations to be performed at baseline, in 




All patient identifiers were removed prior to electronic capturing of the data. The data was stored on a password-
protected computer and only the principle investigator had access to this data. Copies of the database were regularly 
made and copies were kept in a locked cupboard at a site outside the hospital. The data were transformed by members 
of the statistics department, to be compatible with the Stata 14 software for statistical analysis. 
 
Statistical analysis  
 
Statistical analysis was performed with Stata14 (StataCorp. 2015. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP). Standard descriptive analysis, including measures of central tendency (mean, median, 
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proportions) and dispersion (standard deviations [SD], interquartile ranges [IQR] and 95% confidence intervals [CI]) 
were performed for measured variables (depending on whether the variables were normally distributed or not) while 
frequencies and proportions were described for categorical variables. For comparisons based on mortality, chi-squared 
tests (or exact tests for sparse data) and t and rank sums for parametric and non-parametric data were used. Analysis 
of survival and mortality used time to event methods including Kaplan-Meier graphs. For patients lost to follow up, 
survival was censored at the last known date to be alive. For all hypothesis tests a significance level of 0.05 was used 
while the 95% CI were reported were necessary. The p values reported include analysis of all data including data 
‘missing’. 
Ethical considerations  
 
Approval from the Health Research Ethics Committee of Stellenbosch University and the hospital management of 
Tygerberg Hospital was obtained prior to the collection of data. (Appendix 5) There was a waiver of individual 
informed consent due to the retrospective nature of the study, as it had no interventions and minimal risk. Children 
were already cared for by the treating clinicians.  
 
Study clinicians created anonymity by giving each case a case number linked to their hospital number on a separate 
data sheet. This was stored separately from the case report forms. Case report forms and statistical spreadsheets 






























We identified 227 possible cases of acute myocarditis/DCMO. Sixteen children with a clinical diagnosis of 
myocarditis were excluded because they died soon after admission, prior to ECHO and without an autopsy being 
performed. Ninety-four (94) further children were excluded because they did not meet the diagnostic criteria for the 
study, had inadequate records to determine whether they met the inclusion criteria, or were diagnosed outside of the 
study period, or at another hospital. (Figure 1) 
 
Of the remaining 117 children, 92 (78.6%) were included due to ECHO findings only, 19 (16.2%) on histology only 



























Figure 1: Screening, inclusion and outcomes of children in study 
 
 
Demographics and description of cohort 
 
The median age of the 117 cases at diagnosis was 18.9 months (IQR 8.9-52.2), with 90 (76.9%) under 5 years of age 
and 42 (35.9%) less than 12 months of age at diagnosis. There were 65 (55.6%) females. The median weight-for-age 
z-score at diagnosis was -1.13 (IQR -2.6 - 0.3). There was no difference in the age, male: female ratio or weight for 
age z- score between those children that died and to those that survived. (Table 1)  
 
Excluded: n=110 (48.5%) 
16 (14.5%): Died without investigation 
94 (85.5%): Reviewed but criteria not met 
Included: n=117 (51.5%) 
92 (78.6%): ECHO only 
4 (3.4%): ECHO and Biopsy (antemortem) 
2 (1.7%): ECHO and Histology (postmortem) 
19 (16.2%): Histology only (postmortem) 
n=52 (44.4%): Total died during study 
period 
n=65 (55.6%): Survived study period 
n=227: Children identified 
n=38: Died at first admission 
(32.5% of children, 73% of deaths) 
n=14: Died subsequently 
(12% of children, 27% of deaths) 
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Sixty-four children (54.7%) were from inside the Cape Town metropolitan area and 28 (23.9%) were from outside the 
metropolitan region. In 25 children we could not determine the residential area from the record. 
 
The HIV status was known in 80 children, in the remaining 37 (31.6%) no record of a laboratory or point of care test 
could be found. Twenty-four of 117 (20.5%) children were known to be HIV exposed and of these 7 (29.2%) were 
HIV-infected. Four of the 7 HIV-infected children (57.1%) were receiving antiretroviral therapy. Other conditions 
included current therapy for tuberculosis (10.2%), current or previous therapy for childhood malignancies (4.3%) and 
being born prematurely (11.1%). (Table 1) 
 
The Paediatric Emergency Centre at Tygerberg Hospital was the first contact point at Tygerberg Hospital for 52 
(44.4%) of the cases and the PICU for 25 (21.4%). Twenty-nine patients (24.8%) were initially diagnosed directly in 
one of the paediatric wards and not in the PICU or Emergency centre. PICU as the initial contact area was predictive 
of death in univariate analysis (p=0.001).  
 
Table 1: Demographic and description of cohort  
 
  Total Survived Study  Died  P value 
Number (%) 117 (100%) 65 (55%) 52 (45%)  
Age: Median months (IQR1) 18.9 (8.9-52.2) 21.6  (9.1-46.0) 15.9 (7.3-55.0) 0.270 
Less than 12 months 42 (35.9) 20 (47.6) 22 (52.4) 0.530 
1 year-5 years 48 (41.0) 30 (62.5) 18 (37.5) 
5-10 years 17 (14.5) 10  (58.8) 7 (41.2) 
Older than 10 years 10 (8.6) 5 (50.0) 5 (50.0) 
Sex: Female 65 (55.6) 37 (56.9) 28 (43.1) 0.739 
Weight z score Median (IQR1) -1.1 (-2.6- 0.3) -1.3 (-2.8-0.1) -0.9 (-2.2-0.4) 0.475 
HIV2 infected  7 (5.9) 3 (42.9) 4 (57.1) 0.450 
On TB3 Treatment 12 (10.3) 8 (66.7) 4 (33.3) 0.184 
Childhood cancer 5 (4.3) 3 (60.0) 2 (40.0) 0.295 
Prematurity 13 (11.1) 6 (46.2 ) 7 (53.8 ) 0.663 
Residential Area   
Inside Metro  64 (54.7) 42 (65.7)  22 (34.4) 0.120 
Outside Metro 28 (23.9) 12 (42.9) 16 (57.1 ) 
First Contact at TBH4   
PICU5 25 (21.4) 8 (32.0) 17 (68.0) 0.001 
Emergency centre 52 (44.4) 33 (63.5) 19 (36.5) 
Paediatric ward 29 (24.8) 22 (75.9) 7 (24.1) 
COPD6 2 (1.71) 1 (50.0)  1 (50.0) 
Not Known 9 (7.7) 1 (11.1) 8 (88.9) 
Abbreviations: IQR1: Interquartile range, HIV2: Human Immunodeficiency virus, TB3: Tuberculosis, TBH4: Tygerberg Hospital, PICU5: Paediatric 
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Presenting complaints and initial clinical findings   
 
Non-specific symptoms were common including fast breathing (94.2%), cough (83.1%), lethargy (68.5%) and poor 
feeding (66.1%). (Table 2)  Over a quarter of children (28.2%) had a short duration of symptoms and presented for 
care within 3 days of the onset of symptoms, of these 10 (8.6%) presented on day 1. (Table 3) Forty (34%) of children 
however had symptoms for more than one week and in 13 (11.1%) symptoms were present for more than a month 
prior to diagnosis. This shows the range in timing of presentation although duration of symptoms was not predictive 
of outcome (p=0.444). Few (16%) children had two or more health care contacts prior to the diagnosis and the time 
between the onset of symptoms and diagnosis was not greater for children who were referred from outside the Cape 
Town Metro (p=0.444). Twenty-five of the 38 children (65.8%) who died at TBH during their first admission died 
within the first 24 hours of admission. 
 
Table 2: Most common presenting symptoms  
Symptom Number of cases 
presence/absence of 
symptom was documented 
n (% of 117) 
Number of cases 
symptom present in 
 











Fast breathing 86 (73.5) 81 (94.2) 45 (55.6) 36 (44.4) 0.133 
Cough 83 (71.0) 69 (83.1) 44 (63.8) 25 (36.2) 0.152 
Lethargy/fatigue 51 (43.6) 35 (68.6) 23 (65.7) 12 (34.3) 0.276 
Poor feeding 62 (53.0) 41 (66.1) 25 (61.0) 16 (39.0) 0.721 
Oedema 49 (41.9) 27 (55.1) 17 (63.0) 10 (37.0) 0.275 
Fever 73 (62.4) 34 (46.6) 21 (61.8) 13 (38.2) 0.339 
Loss of weight 42 (35.9) 17 (40.5) 11 (64.7) 6 (35.3) 0.264 
Vomiting 68 (58.1) 27 (39.7) 18 (66.7) 9 (33.3) 0.420 
Flu like symptoms 42 (35.9) 16 (38.1) 11 (68.8) 5 (31.2) 0.150 
Sweating 43 (36.8) 16 (37.2) 10 (62.5) 6 (37.5) 0.199 
Abdominal pain 40 (34.2) 12 (30.0) 8 (66.7) 4 (33.3) 0.256 
Irritability 35 (29.9) 10 (28.6) 7 (70.0) 3 (30.0) 0.247 
Diarrhoea 62 (53.0) 14 (22.6) 12 (85.7) 2 (14.3) 0.059 
Coryza 43 (36.8) 11 (25.6) 8 (72.7) 3 (37.3) 0.316 
Tight chest 35 (29.9) 8 (22.9) 5 (62.5) 3 (37.5) 0.439 
Rash 41 (35.0) 9 (22.0) 8 (88.9) 1 (11.1) 0.083 
Cyanosis 32 (27.4) 6 (18.8) 2 (33.3) 4 (66.7) 0.100 
Seizure 34 (29.1) 5 (14.7) 3 (60.0) 2 (40.0) 0.303 
Palpitations 33 (28.2) 4 (12.1) 3 (75.0) 1 (25.0)  0.210 
Chest pain 31 (26.5) 3 (9.7) 2 (66.7) 1 (33.3) 1.000 
Hemiplegia 30 (25.6) 2 (6.7) 2 (100.0) 0 (0.0) 0.159 
Conjunctivitis 31 (26.5) 2 (6.5) 0 (0.0) 2 (100.0) 0.089 
Arthralgia 29 (24.8) 1 (3.4) 1 (100.0) 0 (0.0) 0.207 
Haemoptysis 30 (25.6) 1 (3.3) 0 (0.0) 1 (100.0) 0.130 
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Table 3: Duration of symptoms and health care contact prior to diagnosis and time to clinical suspicion at TBH 
 Total 











1-3 days 33 (28.2) 21 (63.6) 5 (15.2) 7 (21.2) 0.444 
4-6 days 14 (11.9) 8 (57.1) 5 (35.7) 1 (7.2) 
7-14 days 18 (15.4) 10 (55.6) 5 (27.8) 3 (16.7) 
14-28 days 9 (7.7) 6 (66.7) 3 (33.3) 0 (0.0) 
> 1 month 13 (11.1) 7 (53.9) 1 (7.7) 5 (38.5) 
2 or more healthcare contacts  
prior to presentation 
16 (13.7) 13 (81.2) 3 (18.8) 0  (0.0) 0.219 
Admission to peripheral hospital 
> 24 hours with incorrect 
diagnosis   
10 (8.6) 3 (30.0) 7 (70.0) 0 (0.0) 0.049 
 
The common clinical signs (Table 4) suggestive of possible cardiac disorder included displaced apex beat (92.1%) 
cardiovascular instability (85.7%) and clinical signs of cardiac failure (95%). Blood pressure was poorly documented 
in the doctors’ notes and only noted in 69 (59%) of case files (nursing notes were not reviewed). Of these children 
18.3% (n=15) were hypotensive for their age. Signs of central nervous system dysfunction were common and 
included a GCS <8/15 (17.4%), seizures on admission (19.5%) and hemiplegia (15.2%). Tachycardia for age 
(p=0.015), cardiovascular instability (p= 0.005), cardiac failure (p=0.023), a displaced apex beat (p= 0.002) were 
predictive of death on univariate analysis. (Table 4) 
 
Table 4: Clinical signs at initial presentation to Tygerberg Hospital  
Clinical Sign 
 
Presence or absence 












Tachypnoea for age  63 (53.9) 62 (98.4) 42 (67.7) 20 (32.3) 0.333 
Tachycardia for age  83 (70.9) 75 (90.4) 47 (62.7) 28 (37.3) 0.015 
Systolic Hypotension  69 (59.0) 15 (18.3) 8 (53.3) 7 (46.7) 0.154 
Cardiovascular Instability  105 (89.7) 90 (85.7) 49 (54.4) 41 (45.6) 0.005 
Cardiac Failure  99 (84.6) 94 (95.0) 58 (58.6) 36 (38.4) 0.023 
Displaced Apex  89 (76.1) 82 (92.1) 51 (62.2) 31 (37.8) 0.002 
Hepatomegaly  90 (76.9) 83 (92.2) 53 (63.9) 30 (36.1) 0.105 
Raised JVP1  20 (17.1) 17 (85.0) 13 (76.5) 4 (23.5) 0.150 
Crackles  75 (64.1) 57 (76.0) 34 (59.7) 23 (40.3)  0.076 
Oedema  67 ( 57.3) 49 (73.1) 28 (57.1) 21 (42.9) 0.199 
Wheeze  63 (53.9) 24 (38.1) 14 (58.3) 10(41.7) 0.297 
CNS Disease       
Depressed LOC2  69 (59.0) 12 (17.4) 8 (66.7 ) 4 (33.3) 0.112 
Seizures  36 (30.8) 7 (19.5) 3 (42.9) 4 (57.1) 0.221 
Hemiplegia  33 (28.2) 5 (15.2) 4 (80.0) 1  (20.0) 0.137 
Abbreviations: JVP1: Jugular venous pressure, LOC2: Level of consciousness.  
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Imaging and special investigations 
CXR on admission 
 
All the 97 CXRs available for review were abnormal. (Table 5) Six (6.2%) had isolated cardiomegaly with no other 
abnormalities. Ninety (91.8%) displayed cardiomegaly, whilst plethora was seen in 75 (77.3%), pleural effusion in 59 
(60.9%) atelectasis/collapse 28 (28.9%) and/or airway narrowing in 42 (43.3%) CXRs.  The median cardiothoracic 
ratio was 69.9% (IQR 63.7%-74.6%) and the abnormal radiological signs were not different between those that died 
or those that survived. (Table 5) 
 








Cardiothoracic Ratio % Median (IQR2) 69.9 (63.7-74.6) 69.9 (62.4-74.9) 70.3 (63.7-74.6) 0.217 
CXR1 isolated cardiomegaly n (%) 6 (6.2) 4 (66.7) 2 (33.3) 0.647 
Increased cardiothoracic ratio for age n (%) 90 (91.8) 46 (51.7) 44 (48.3) 0.560 
Plethora n (%) 75 (77.3) 37 (49.3) 38 (50.7) 0.178 
Pleural effusions n (%) 59 (60.9) 30 (50.9) 29 (49.1) 0.329 
Atelectasis/collapse n (%) 28 (28.9) 15 (53.6) 13 (46.4) 0.358 
Airway narrowing n (%) 42 (43.3) 26   (61.9) 16 (38.1) 0.098 
Abbreviations: CXR1: Chest x-ray/radiograph, IQR2: Interquartile range 
 
ECG on admission 
 
Fifty-five admission ECGs were available and were reviewed. (Table 6) Only three (5.5%) ECGs were normal. The 
median heart rate was 144 (IQR 130-166) with 50 (90.91%) showing a sinus rhythm. Five children (9.1%) had an 
arrhythmia, 53 (96.4%) had chamber enlargement and 30 (54.5%) had features suggestive of ischaemia.    
 
Table 6: Description of first electrocardiograph at Tygerberg Hospital 
 Description of abnormality Number 
n (% of 55) 
ECG1 abnormal  Any ECG abnormality 52 (94.6) 
2 or more abnormalities >2 ECG abnormalities 39 (70.9) 
Tachycardia for age Heart rate >max HR2 for age 31 (56.4) 
Prolonged QTc3  Prolonged QTc >470ms 2 (3.6) 
Any rhythm abnormality apart 
from sinus tachycardia 
n=5 (9.1%) 
Ventricular Tachycardia 2 (3.6) 
Supraventricular Tachycardia 1 (1.8) 
Other arrhythmia 2 (3.6) 
Abnormal axis 
n=7 (12.7%) 
Left 1 (1.8) 
Right 5 (9.1) 
Extreme left 1 (1.8) 
Any chamber enlargement  
n=53 (96.4%) 
RVH4 9 (16.4) 
LVH5 31 (56.4) 
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RA6 enlargement 12 (21.8) 
LA7 enlargement 1 (1.8) 
Any features of ischemia  
n=30 (54.5%) 
Q wave 4 (7.3) 
ST abnormality 7 (12.7) 
Upright T in V1 2 (3.6) 
Upright T in V2 17 (30.9) 
*Abbreviations: ECG1: Echocardiogram, HR2: Heart rate, QTc3: Calculated using Fredericia method, RVH4: Right ventricular hypertrophy, LVH5:  
Left ventricular hypertrophy, RA6: Right atrial, LA7: Left atrial. 
 
 
Echocardiography findings at diagnosis 
 
Ninety-eight cases (83.8%) had an echocardiogram as part of their diagnostic work-up. (Table 7) Due to the study 
inclusion criteria, there were no patients who had a normal initial ECHO, and where chemotherapy (in the context of 
childhood cancer) was the cause of the DCMO, I have reported their first abnormal ECHO as their diagnostic ECHO. 
 
Ejection fraction was the most readily available measurement. Eighty-eight diagnostic EFs and 49 diagnostic SFs 
were documented. The median EF was 24% (IQR 15%-32.5%) with 68.2% of the cases having a diagnostic EF of less 
than 30%. The median SF was 12% (IQR 10%-18%) and was not different in the survivors compared to those that 
died (p=0.099 and p=0.477). (Table 7)  
 
An intracardiac thrombus was noted in 5 (5.1%) children and small pericardial effusions in 13 (13.3%). 
 
Table 7: Echocardiography findings at diagnosis 
 Total Survived Study Died P Value 
EF1 at diagnosis Median (IQR2) n=88 24(15-32.5) 26.5 (18-35) 22 (15-26) 0.099 




Less than 20% 35 (39.8) 23 (65.7) 12 (34.3) 0.040 
21-30% 25 (28.4) 19 (76.0) 6 (24.0) 




Less than 10% 12 (24.5) 7 (58.3) 5 (41.7) <0.001 
11-20% 29 (59.2) 19  (65.5) 10 (34.5) 
21-25% 8 (16.3) 4 (50.0) 4 (50.0) 
Abbreviations: EF1: Ejection fraction, IQR2: Interquartile range, SF3: Shortening fraction 
 
Follow- up echocardiography of survivors  
 
Improvements in the EF and SF values were noted when comparing the diagnostic percentages to the latest ECHO 
percentages. (Table 8) The median EF at the latest ECHO was 53% (IQR 35%-59%) with the latest SF median being 
25% (IQR 17.5%-33%). The change in EF from diagnosis to latest ECHO was a median increase of 22.5% (IQR 9%-
34%) and SF increase a median of 10% (IQR 2%-16%). Children that survived had a significantly higher latest EF 
than those that died (p=<0.001) in univariate analysis. The time between the first and latest ECHO was a median of 
372 days (IQR 125-789). 
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Table 8: Echocardiography findings of 65 study survivors  
  ECHO1 at diagnosis  
n=65 (%)  
Last available ECHO1 
n=65 (%) 
EF2 Category  
 
<20% 23 (35.4) 11 (16.9) 
21-30% 19 (29.2) 10 (15.4) 
31-55% 23 (35.4) 27 (41.5) 
>55%  17  (26.2) 
Abbreviations: ECHO1: Echocardiography EF2: Ejection fraction, IQR3: Interquartile range, SF4: Shortening fraction 
 
Other investigations at time of diagnosis  
 
In 48 children with a documented pH (arterial), a median pH of 7.35 (IQR 7.25-7.43) was demonstrated. Overall there 
was no significance in initial pH between those who died and those that survived the study, however seventy-five 
percent of the cases with a pH of less than 7.15 on admission died (p=0.035). (Table 9) The median serum lactate 
level (n=51) was 3 (IQR 2.7-6.0) with 83% of those with a serum lactate great than 10mmol/l dying, although this was 
not statistically significant (p=0.068). (Table 9) There were 30 children who had both a lactate greater than 3 and a pH 
less than 7.35 but this also did not predict poor outcome (p=0.139). 
 
The children’s length was not collected and therefore the glomerular filtration rate was not calculated, but serum 
creatinine and creatinine kinase were more likely to be raised in children who died (p= 0.002 and p= 0.007). Three 
children required peritoneal dialysis during their ICU stay. Fourteen children 14/91 (15.4%) had positive bacterial 
blood cultures at the time of admission and 9/14 (64.3%) died during the study. (Table 9) 
 
Table 9: Other investigations at time of diagnosis 









pH >7.35 48 (41.0%) 27 (56.3) 17 (63.0) 10 (37.0) 0.035 
pH 7.15-7.34 13 (27.1) 9 (69.2) 4 (30.8) 
pH <7.15 8 (16.7) 2 (25.0) 6 (75.0) 
Lactate  3-5 51 (43.6%) 20 (39.2) 12 (60.0) 8 (40.0) 0.068 
Lactate  5.1-10 10 (19.6) 6 (66.0) 4  (40.0) 
Lactate  >10 6 (11.8) 1 (16.7) 5 (83.3) 
CRP1 91 (77.8) 56 (61.5) 26 (46.4) 30 (53.6) 0.098 
Serum creatinine  108 (92.3) 82 (75.9) 37 (45.1) 45 (54.9) 0.002 
CK2   85 (72.7) 46 (54.1) 21 (45.7) 25 (54.3) 0.007 
Troponins  54 (46.2) 27 (50.0) 17 (63.0) 10 (37.0) 0.611 
AST3  81 (69.2) 69 (85.2) 35 (50.7)  34 (49.3) 0.450 
Blood cultures   91 (77.8) 14 (15.4) 4 (28.6) 10 (71.4) 0.089 
Basic metabolic screen  64 (54.7) 2 (3.1) 1 (50.0) 1 (50.0) 0.598 
Autoimmune Screen  34 (29.1) 3 (8.8) 2 (66.7) 1 (33.3) 0.969 
Abbreviations:  CRP1: C-reactive protein, CK2: Creatinine kinase, AST3: Aspartate transaminase 
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Investigations to determine possible viral cause 
 
Investigations for viral pathogens were not performed on all children.  Of the viral studies done on 95 cases, 73 
(76.8%) were positive for one or more viruses and 37 (38.9%) positive for multiple viruses. (Table 10) The most 
common viruses found were cytomegalovirus (CMV), rhinovirus, respiratory syncytial virus and parvovirus. Of all 
the viral investigations performed there was not a single virus that was more common than others in those children 
who died. (Table 10) In children with CMV on a respiratory or urine specimen, it was considered to be a significant 
infection only if the viral load in the blood was shown to be more than 1000 copies/mL (Log 3). 
 
Table 10: Viral studies performed 
Organism Test Performed 
n (% of 117) 
Positive 






CMV1 Resp Panel PCR2* 69 (59.0) 20 (29.0) 9 (45.0)  11 (55.0) 0.556 
 Urine  7  (6.0) 2 (28.6) 1 (50.0) 1 (50.0) 0.762 
 Blood IgM 49 (41.9 ) 4 (8.2) 1 (25.0) 3 (75.0) 0.002 
 Blood Viral Load 40 (34.2) Log <3 19 (47.5) 13 (68.4) 6 (31.6) 0.432 
 Log3.0-4.0 9 (22.5) 6 (66.7) 3 (33.3) 
Log4.1-5 5 (12.5) 1  (20.0) 4 (80.0) 
Log >5 2 (5.0) 1 (50.0) 1 (50.0) 
Rhinovirus Resp Panel PCR2 69 (59.0) 19 (27.5) 11 (57.9) 8 (42.1) 0.874 
RSV3 Resp Panel PCR2 69 (59.0) 9  (13.0) 4 (44.4) 5 (55.6) 0.783 
Adenovirus Resp Panel PCR2 69 (59.0) 5 (7.2) 5 (100.0) 0 (0.0) 0.175 
Influenza Resp Panel PCR2 69 (59.0) 2 (2.9) 1 (50.0) 1 (50.0) 0.655 
Parainfluenza Resp Panel PCR2 69 (59.0) 4 (5.8) 1 (25.0) 3 (75.0) 0.929 
Coronavirus Resp Panel PCR2 69 (59.0) 3 (4.3) 2 (66.7) 1 (33.3) 0.981 
Enterovirus Resp Panel PCR2 69 (59.0) 3 (4.4) 2 (66.7) 1 (33.3) 0.624 
Stool Viral Screen 31 (26.1) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 
Coxsackie Serology   50 (42.7 ) 3 (6.0) 3 (100.0) 0 (0.0) 0.137 
Mumps IgM 50 (42.7) 3 (6.0) 3 (100.0)  0 (0.0) 0.031 
 PCR2 18 (15.4) 1 (5.6) 1 (100.0) 0 (0.0 ) 0.807 
Measles IgM 10 (8.5) 1 (10) 1 (100.0) 0 (0.0) 1.000 
Rubella IgM 54 (46.2) 1 (1.9) 1 (100.0) 0 (0.0) 0.424 
Parvo B19 IgM 44 (37.6) 11 (25.0) 8 (72.7) 3 (27.3) 0.131 
 PCR2 41 (35.0) 17 (41.5) 14 (82.3) 3 (17.6) 0.436 
EBV4 IgM 58 (49.6) 7 (12.1) 4 (57.1) 3 (42.9) 0.025 
Herpes 
(HHV65) 
PCR2 8 (6.8) 1 (12.5) 1(100.0) 0 (0.0) 0.282 
Hep A IgM 9 (7.7) 2 (22.2) 0 (0.0) 2 (100.0) 0.027 
Multiple Viruses isolated 37 (31.6)  23 14 0.926 
*Resp Panel PCR:  Respiratory viral panel PCR 
Abbreviations: CMV1: Cytomegalovirus, PCR2: Polymerase chain reaction, RSV3: Respiratory syncytial virus, EBV4: Epstein Barr virus, HHV65: 
Human herpes virus  





Abbreviations: CMV: Cytomegalovirus, RSV: Respiratory syncytial virus, EBV: Epstein-barr virus, HSV: Herpes simplex virus, Other: HHV-6: 
Human herpes virus-6/measles and metapneumovirus 
 
Figure 2: Bar chart of viruses in the 95 tested patients 
 
Children with viral myocarditis/DCMO associated with viral myocarditis, were not younger than the general cohort, 
with a median age at diagnosis of 16.1 months (IQR 8-28.1). The 6 children with CMV as the only virus found and 
who had a viral load of more than Log >3 copies per mL, were younger than the general cohort median age 5.6 
months (IQR 2.4-11.9). There were 2 patients with equivocal EBV IgMs and 1 with equivocal Rubella IgM.  
 
Proposed causes of acute myocarditis/DCMO 
 
With reviewing both the “given” proposed causes in the case files and on creating case definitions for the purpose of 
this study, on retrospective classification it was found that 54/117 (36.7%) of children had probable viral myocarditis. 
4/7 (57.1%) of the HIV-infected children also had presumed viral causes not HIV related. In 34/117 (29.1%) of cases, 
either their investigations/work up was not complete hence the true cause could not be determined, or their full screen 
(except genetic testing) was negative hence the “idiopathic” classification. (Table 11) Death from viral myocarditis 
was not more common than death from the other causes. Chemotherapy (in the context of childhood cancer) was 
causal in 5 (4.3%) and arrhythmias and nephritis in 4.3% and 3.4% respectively. Other presumed causes (n=8) (6.8%) 
included autoimmune disease, metabolic disease and in two cases proximity to early childhood vaccination was noted. 
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Abbreviations: HIV1: Human immunodeficiency virus, ARVs2: Antiretrovirals 
 
Management/interventions and outcomes of cohort 
 
Thirty-seven children 37/117 (31.6%) died during the first admission to hospital. Of the 52/117 (44.4%) children who 
died during the study period, 6/52 (11.5%) died in the emergency centre and 34/52 (65.4%) in the PICU. The median 
length of hospital stay for the first admission was 12 days (IQR 8-20 days). Children who died stayed 5 days (IQR 1-
15 days) and 25/52 deaths (48.1%) occurred in the first 24 hours. (Tables 12 and 13)  
 
Seventy of 108 (64.8%) children were admitted to PICU on their first admission with the median duration of PICU 
stay being 7 days (IQR 4-11 days). In 9 children the PICU admission status was unclear. The mortality of those 
admitted to the PICU was 51.4% (36/70). This was significantly different from those that survived PICU 34/70 
(48.6%) (p=0.002). In PICU 46/107 (43%) cases were ventilated with a median duration of ventilation being 4 days 
(IQR 1-5 days). 
 
Seventy of 101 children (69.3%) required inotropic support during their hospitalization with 59/94 (62.7%) receiving 
dopamine and/or dobutamine and 23/89 (25.8%) also requiring adrenalin infusions. Milrinone was used in 22/88 
(25.0%) cases. Thirty-three 33/101 (32.7%) required 2 or more inotropes during their first admission.  Generally 
inotropes were given in PICU but the above represents all inotropic support even if started in the emergency unit 
and/or in the wards. PICU admission (p=0.002), being ventilated (p=<0.001) and receiving inotropic support 
(p=<0.001) (including more than one inotropic drug and adrenaline infusion) were all associated with increased 
mortality in the univariate analysis. Adrenalin infusion was associated with 87% mortality (p=<0.001). Thirty (25.6%) 
children required cardio-pulmonary resuscitation (CPR) during their first admission. Of those requiring CPR 73.3% 
died. (Table 12) 
 
 Total 






Presumed Viral myocarditis 54 (36.7%) 33 (61.1) 21 (38.9) 0.503 
Not determined 31 (26.5%) 12 (38.7) 19 (61.3) 
Idiopathic 3 (2.6%) 2 (66.7) 1 (33.3) 
HIV1 Disease/ARVs2 3 (2.6%) 2 (66.7) 1 (33.3) 
HIV1+ with a virus 4 (3.4%) 1 (25.0) 3 (75.0) 
Cancer/Chemotherapeutic Drugs 5 (4.3%) 3 (60.0) 2 (40.0) 
Arrythmia 5 (4.3%) 4 (80.0) 1 (20.0) 
Nephritis 4 (3.4%) 3 (75.0) 1 (25.0) 
Autoimmune 3 (2.6%) 2 (66.7) 1 (33.3) 
Metabolic Disease 2 (1.7%) 1 (50.0) 1 (50.0) 
Presumed Vaccine related 2 (1.7%) 2 (100.0) 0 (0.0) 
Congenital/Perinatal 1 (0.9%) 1 (100.0) 0 (0.0) 
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Diuretics were used in 89 (94.6%) of cases, captopril in 67 (79.7%) and digoxin and b-blockers in 9 (15.0%) and 2 
(3.3%) respectively. Steroids were used in 11 (9.4%) cases either for blood pressure support or immune modulation 
and intravenous immune globulin in 2 (1.7%) cases. The use of diuretics, (p=<0.001) captopril, (p=<0.001) and 
digoxin (p=0.015) reflected initial survival. (Table 12) 
Aspirin was given to 36 (40.9%) cases whereas warfarin to only 5 (4.3%) of the cases. Thirty-one (49.2%) received B 
vitamins and/or carnitine orally. Twenty-one (33.9%) received transfusion of blood products. (Table 12)  
 
Table 12:  Outcomes and management of cases of myocarditis/DCMO during first admission  
 
Interventions 
(n refers to the number of patients in which 
interventions were provided/indicated in 
medical records) 
Total Survived Study Died P Value 
Duration of 1st admission Median days (IQR1) 10  (3-18) 12 (8-20) 5 (1-15) 0.0007 








Survived 1st admission 80 (68.4)   
Died first admission  37 (31.6)  
PICU2 admission n=108 (92.3) 70 (64.8) 34 (48.6) 36 (51.4) 0.002 
Ventilated n=107 (91.5) 46 (43.0) 17 (37.0) 29 (63.0) <0.001 
Duration of ventilation (days) Median (IQR1) 4 (1-5 )   5 (4-9) 2 (1-4) 0.0018 
Inotropic support n=101 (86.3) 70 (69.3) 33  (47.1) 37 (52.9) <0.001 
Dopamine and/or 
Dobutamine n=94 (80.3) 
59 (62.8) 31 (52.5) 28 (47.5) <0.001 
Adrenalin n=89 (76.1) 23 (25.8) 3 (13.0) 20 (87.0) <0.001 
Milrinone n=88 (75.2) 22 (25.0) 10 (45.5) 12 (54.5) 0.020 
>2 Inotropes n=101  (86.3) 33 (32.7) 11 (33.3) 22 (66.7) 0.002 
Non-invasive oxygen support n=92 (78.6) 73 (79.4) 45 (61.6) 28 (38.34) 0.082 
Cardiac arrest/CPR3 n=117 (100.0) 30 (25.6) 8 (26.7 22 (73.3) <0.001 
Diuretics n=94 (80.3) 89 (94.7) 61 (68.5) 28 (31.5) <0.001 
Captopril n=84 (71.8) 67 (79.8) 49 (73.1) 18 (26.9) <0.001 
Beta-Blockers n=60 (51.3) 2 (3.3) 2  (100.0) 0 (0.0) 0.313 
Digoxin n=60 (51.3) 9 (15.0) 9 (100.0) 0 (0.0) 0.015 
Steroids  n=56 (47.9) 11 (19.9) 6 (54.5) 5 (45.5) 0.929 
Polygam n=51 (43.6) 2 (3.9) 1 (50.0) 1 (50.0) 0.950 
B-Vitamins/Carnitine n=63 (53) 31 (49.2) 18 (58.1) 13 (41.9) 0.502 
Clexane/Warfarin n=90 (76.9) 5 (5.6) 3 (60.0) 2 (40.0) 0.645 
Aspirin n=88 (75.2) 36 (40.9) 23 (63.9) 13 (36.1) 0.317 
Transfused any Blood Products n=62 (53.0) 21 (33.9) 11 (52.5) 10 (45.5) 0.880 
Abbreviations: IQR1: Interquartile range, PICU2: Paediatric intensive care unit, CPR3: Cardiopulmonary resuscitation 
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PICU admission 70  36 14  5  5  6 3  1  0.157 
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Abbreviations: IQR: Interquartile range, HIV2: Human immunodeficiency virus, PICU3: Paediatric intensive care unit, EF4: Ejection fraction, CCF5: 
Congestive Cardiac failure, CVS6: Cardiovascular system, LOC7: Level of consciousness, CPR8: Cardiopulmonary resuscitation 
*post hoc analysis using Dunn test with Bonferroni adjustment for multiple comparisons, showed no significant differences between the groups 




Children diagnosed on postmortem alone 
 
There were 19 children diagnosed only at postmortem with no diagnostic ECHO prior to this. (Table 14) Twelve of 
these infants died on day one of admission which may support the rapidity in their disease progression, hence little 
time for a confirmative ECHO, or that they presented late or were misdiagnosed. Five of the 19 children (26%) were 
under 3 months of age. Three of these 5 infants had admissions between 29 and 58 days, yet despite extensive 
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Table 14: Subset of children diagnosed on postmortem alone 
 




Age in months Median (IQR1) 15.9 (7.3-55.0) 10.6 (2.2-28.8) 
Less than 12 months 22 (42.3) 10 (52.6) 
1 year-5 years 18 (34.6) 5 (26.3) 
5-10 years 5 (9.6) 1 (5.3) 
Older than 10 years 5 (9.6) 3 (15.8) 
Sex: Female 28 (53.8) 8 (42.1) 
HIV2 infected 4 (7.7) 2 (22.2) 
Place of arrival at TBH4   
PICU5 17  (32.7) 5 (26.3) 
Emergency centre 19 (36.5) 6 (31.6) 
Paediatric ward 7 (13.5) 1 (5.3) 
Not Known 8 (15.4) 7 (36.8) 
Duration of symptoms   
<3 days 16 (31.0) 6 (31.6) 
4-6 days 7 (13.5) 1 (5.3) 
7-14 days 5 (9.6) 2 (10.5) 
15-30 2 (3.8) 0 (0.0) 
> 1 month 4 (7.7) 1 (5.3) 
Unclear 18 (34.6) 9 (47.4) 
On arrival   
Intubated on arrival 12 (23.1) 5/11 (45.5) 
Cardiovascular instability 41 (78.8) 11/12 (91.7) 
 CCF7 36 (69.2)  8/9 (88.9) 
Delay in diagnosis 20  (38.5) 4/8 (50.0) 
Management   
Admitted to PICU5 36 (69.2) 9/13 (69.2) 
Intubated/Ventilated 29 (55.8) 10/11 (91.0) 
Inotropes 37 (71.2) 9/10 (90.0) 
Adrenalin 20 (38.5) 8/10 (80.0) 
2 or more inotropes 22 (42.3) 6/8 (75.0) 
Died day 1 25 (48.1) 12 (63.2) 
Died days 2-7 7 (13.5) 4 (21.1) 
Died > day 7 20 (38.5) 3 (15.8) 
Investigations   
Positive Blood cultures 10 (19.2) 7/14 (50.0)   
Staphylococcus aureus 2 (20.0) 2 (28.6) 
Streptococcus pneumoniae 2 (20.0) 1 (14.3) 
MRSA10 1 (10.0) 1 (14.3) 
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ESBL11 klebsiella 2 (20.0) 1 (14.3) 
Haemophilus influenza and streptococcus 
pneumoniae 
1 (10.0) 1 (14.3) 
Candida and klebsiella 2 (20.0) 1 (14.3) 
Viral screen positive 26 (50.0) 7/10 (70.0) 
Parainfluenza 3 (11.5) 3 (42.9) 
CMV12 13 (50.0) 3 (42.9) 
CMV12 (significant) 8 (30.8) 2 (28.6) 
Parvovirus B19 3 (11.5) 1 (14.3) 
Rhinovirus 7 (26.9) 1 (14.3) 
Hepatitis A 1 (3.8) 1 (14.3) 
Metabolic screen positive 1 (1.9) 0 (0.0) 
Autoimmune screen positive 1 (1.9) 0 (0.0) 
CXR13 abnormal  41 (33.8) 12/12 (100.0) 
ECGs14 done 16 (30.7) 0 (0.0) 
Cause category   
Viral 21 (40.4) 4 (21.1) 
HIV2 +virus 4 (7.7) 2 (10.5) 
Not determined 19 (36.5) 13 
Days of 1st admission median (IQR1) 5 (1-15) 1 (0-5) 
Place of death   
PICU5 34 (65.4) 10 (52.6) 
Emergency centre 6 (11.5) 4 (21.1) 
Wards 3 (5.8) 1 (5.3) 
Other 9 (17.3) 4 (21.1) 
Abbreviations: IQR1: Interquartile range, HIV2: Human Immunodeficiency virus, TB3: Tuberculosis, TBH4: Tygerberg Hospital, PICU5: Paediatric 
Intensive Care unit, COPD6: Cardiac outpatient department, CCF7: Congestive cardiac failure CK8: Creatine kinase, CRP9: C-reactive protein, 
MRSA10 : Methicillin resistant staphylococcus aureus, ESBL11: Extended-spectrum-beta-lactamases, CMV12: Cytomegalovirus, CXR13: Chest x-
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Table 15: Summary of five children under the age of three months: diagnosed on postmortem 
 
Case Service Duration in 
hospital 
(days) 





1 NICU2 6 6 No 27 week gestation neonate 
HIV3 exposed but 
uninfected/tuberculosis 
exposed/syphilis but uninfected 
HMD4 
Congenital pneumonia 




28 28 Yes 33 week gestation neonate 
HIV3 exposed but uninfected 
Apnoeas with presumed sepsis 
Encephalopathy on EEG 
Deranged liver function 
3 Neonatal 
Ward 
58 58 Yes 27 week gestation infant 
HIV-infected 
Jaundice 
Treated for necrotizing enterocolitis 
4 NICU2 56 77 No Term infant 
Hirschprung disease on biopsy 
Confirmed blood stream infection 
(MRSA) 
PM6 showed pancarditis with 
macroscopic cardiac abscesses. 
5 PICU5 1 66 No Premature infant (unknown 
gestation)/low birth weight 
Tuberculosis exposed  
Apnoea 
Septic shock 
Confirmed blood stream infection 
(Staphylococcus aureus) 
 
Abbreviations: ECHO1: Echocardiography, NICU2: Neonatal intensive care unit, HIV3: Human immunodeficiency virus, HMD4: Hyaline 
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The Kaplan-Meier plot (Figure 3) illustrates that a large number of deaths occur early. This is seen by the steep 
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Most recent cardiac outpatients follow up  
 
Of the 80 children who survived the first admission, 62 children attended outpatients at least once. (Table 16) The 
median duration of follow up time from first diagnosis was 474 days (IQR 147-820). (Table 16) Fourteen (20.3%) 
recovered and were discharged from cardiac outpatient services, 24 (34.7%) had normalized EF and 24 (34.7%) were 
lost to follow-up. Five children died during or subsequent to follow up, however it was not noted whether these deaths 
were directly related to myocarditis/DCMO or not. 
 
Table 16: Most recent cardiac outpatients follow up for survivors  
Number of patients followed up at COPD1 62  
Number of COPD follow up visits Median (IQR2)  3 (2-7)   
Length of follow up since 1st admission median (days) (IQR2) 474 days (147-820) 
Age of follow up median in months (IQR2) 37 (23-66) 
Symptomatic 18 (29.0) 
Clinical signs of cardiomegaly 34 (54.8) 
Clinical signs of cardiac failure 16 (25.8) 
Medications at follow up 38 (61.3) 
>2 medications on follow up 38 (61.2) 
Furosemide 38 (61.3) 
Spirinolactone 34 (54.8) 
Captopril 36 (58.1) 
Digoxin 10 (16.1) 
Aspirin 17 (27.4) 
Warfarin 3 (4.8) 
Other 11 (17.7) 
Outcome of children who attended COPD1  
Recovered and were discharged from COPD1 14 (22.6) 
Still attend COPD1 with normal EF3 21 (33.9) 
Still attend COPD1 with impaired EF3 5 (8.1) 
Lost to follow up impaired EF3 21 (33.9) 
Lost to follow up normal EF3 3 (4.8) 
Died 5 (8.1) 
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Younger age, admission from outside the metropolitan area (p=0.001), lower EF at diagnosis (p=0.000), CCF at 
diagnosis  (p=0.005), CVS instability (p=0.057), inotrope use and  shock (p=0.000) was associated with death on the 
univariate analysis. On the multivariate analysis renal dysfunction and cardiac failure remained significant. (Table 17) 
 
 
Table 17: Multivariate analysis using death versus survival as outcome 
 Univariate Analysis Multivariate Analysis 
Variable OR2 (95%CI) P Value OR2 (95%CI) P Value 
Place of arrival 0.8 (0.1-29.4)  0.001 0.8 (0.5-1.0) 0.089 
Age at diagnosis 1.0 (1.0-1.0) 0.649   
Weight z score at diagnosis 0.9 (0.9-1.1) 0.461   
HIV1 positive 0.9 (0.5-1.8) 0.824   
Admitted to another hospital prior 0.9 (0.3-2.9) 0.899   
Delay in diagnosis 1.0 (0.4-2.7) 0.924   
Intubated on arrival 2.8 (1.0-7.8) 0.042 0.7 (0.1-5.8) 0.768 
Tachycardia for age 1.8 (0.3-9.5) 0.495   
Depressed level of consciousness 1.4 (0.3-5.5) 0.675   
Cardiovascular instability 5.4 (1.2-25.5) 0.032   
Cardiac failure 2.4 (0.4-15.2) 0.023 85.1 (1.4-5225.9) 0.034 
Displaced apex 3.6 (0.4-31.7) 0.241   
EF3 on diagnosis 3.1 (1.0-9.2) 0.045 3.6 (0.7-18.2) 0.122 
Thrombus ever 1.0 (0.1-12.0) 0.976   
Effusion ever 0.6 (0.1-2.2) 0.415   
Acidosis 1.5 (0.5-4.9) 0.462   
Raised lactate 0.8 (0.4-1.6) 0.535   
Renal dysfunction 3.7 (2.1-21.1) 0.001 8.2 (1.8-38.0) 0.007 
Raised CK4 3.8 (1.5-9.9) 0.005 1.7 (0.6-4.7) 0.274 
ICU5 admission 3.4 (1.4-8.2) 0.006 0.5  (0.0-8.1) 0.640 
Ventilated 5.7 (2.5-13.3) <0.001 0.7 (0.1-4.5) 0.691 
Inotropes 7.6 (2.4-23.9) 0.001 10.1 (0.4-271.9) 0.170 
Dopamine and or Dobutamine 3.6 (1.4-9.6) 0.010   
Adrenalin 24.8 (6.4-95.4) <0.001 6.3 (0.8-52.2) 0.087 
Milrinone 2.4 (0.9-6.4) 0.081   
2 or more inotropes 3.6 (1.5-8.4) 0.003 0.6 (0.1-3.6) 0.561 
CPR6 5.2 (2.1-13.1) <0.001 4.1 (0.9-21.1) 0.061 
Abbreviations: HIV1: Human Immunodeficiency virus, OR2: Odds ratio, EF3: Ejection fraction, CK4: Creatine kinase, ICU5: Intensive care unit, 













This study highlights, for the first time in our setting, the significant burden of disease, as well as mortality and 
morbidity of children with myocarditis and DCMO. We describe a cohort of 117 children with myocarditis/DCMO, 
where the majority of cases were due to probable viral myocarditis or viral myocarditis transitioning/transitioned to 
DCMO. Children were young with a median age at diagnosis of 18.9 months (IQR 8.87-52.2) with 36% younger than 
12 months of age. These children were younger than the RCWMCH PICU cohort where the median age was 27 
months. (24) In both the TBH and RCWMCH cohorts, infants were much younger than the 9.2 years reported in a 
large American cohort. (48) We did not observe the bimodal peak seen in other paediatric cohorts, but as in the US 
cohort, a large number of children were between 6 months and 12 months of age. (48) This age difference may be due 
to a higher burden of common infections with potentially severe outcomes in our community; without the additional 
data on the incidence of these infections, in all the age cohorts, we are unable to explore this further. 
 
At TBH, like in other resource-deplete settings, there is no access to cardiac transplantation, ECMO or ventricular 
assist devices and there is limited access to PICU beds. One of the most striking results found was an overall 44% 
mortality, with the majority, 73%, of these children dying during the initial admission and 48% dying within 24 hours 
of the initial admission. Although we appreciate that myocarditis and DCMO with or without cardiac failure have 
substantial morbidity and mortality (35,36) this high mortality is in stark contrast to the outcomes reported in cohorts 
from the US where survival has improved and is now up to 90% in cohorts of acute myocarditis. (8,49) Locally at the 
RCWMCH PICU, 47% survived PICU admission in a cohort where 55% of patients were ventilated and 100% 
required inotropic support. (24)  
 
Poor perfusion with cardiovascular instability, cardiac failure, low EF, receiving inotropic support, and intubation on 
arrival and required PICU admission were identified as predictors of mortality in univariate analysis. In the 
multivariate analysis renal dysfunction and cardiac failure were the only features that remained significant. Age at 
presentation, cardiac failure and lower EF and SF have consistently been identified as prognostic factors and are 
predictive of death and need for transplantation. (6,13,22,25) Patients with cardiac failure were 4 times more likely to 
succumb or would require transplantation within 1 year of diagnosis. (25) Neonatal presentation (8,22,42) and 
children of older age (13,30,34) have the highest mortality. Our cohort had 6 infants diagnosed under a month old (of 
whom 3 died) and 10 children more than 10 years of age (of whom 5 died), and there was no statistical significance 
between the age overall of those who survived and died in our study. Though the 95% CIs are wide, cardiac failure at 
presentation (OR 85.1 95% CI 1.4-5225.9) (p=0.03) and renal dysfunction (OR 8.2 95% CI 1.8-38.0) (p=0.007) were 
predictive of death.  
 
Finding an EF of less than 30% and/or SF of less than 15%, left ventricular dilatation, and mitral valve regurgitation 
on ECHO are known to be predictive of negative outcomes in other cohorts, but we were not able to show this on 
multivariate analysis. (8) Mortality is also associated with the use of ECMO, VAD, and vasoactive intravenous 
medication, which reflects the most severely ill children. The lower number of children who accessed PICU in this 
study compared to international data does not suggest that these children suffered from less complex disease. The 
result suggested by the higher mortality in our settings, may be due to the local pressures of fewer PICU and high care 
beds as well as understaffing. The high mortality, though not necessarily due to delay in diagnosis, may rather reflect 
a delay in rapid access to intensive care and no access to sophisticated cardiac interventions at the first admission. Six 
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(11.5%) children died in the emergency centre.  
Nineteen children were diagnosed on postmortem alone. These children were slightly younger than the general cohort 
(10 months vs. 18 months) and were critically ill, with 92% showing signs of cardiovascular instability and 89% in 
cardiac failure. Forty-five percent arrived intubated with a further 5 needing intubation on arrival/before dying. Many 
of these children were poorly investigated as to the potential causes of cardiac dysfunction prior to death, due to their 
short duration of admission. In those who were investigated prior to death, high percentages of children showed 
complications in the form of renal dysfunction, a raised CK and a raised CRP. Seven of the 14 who had blood cultures 
taken before death had positive cultures where pathogenic organisms were isolated. The secondary bacterial infections 
may play a role in the disease progression and death in these children, with bacterial infections possibly causing 
additional inflammatory changes and cardiovascular dysfunction. This phenomenon has not been described before in 
myocarditis/DCMO per se, however may have played a role in the rapid deterioration and death of these children. In 
respiratory tract infections, it is well described that frequently viruses and bacteria can co-infect the same host, 
resulting in heightened pathology and severity of illness compared to single infections. (50) This possibly supports the 
use of broad-spectrum antibiotics in children with suspected myocarditis or DCMO, until bacterial infections are 
excluded. There are also children in this cohort who had prior ECHOs that were not suggestive of myocardial failure, 
highlighting the evolution of disease over time and the potential need to repeat ECHO in some cases. These children 
also highlight the important role of the postmortem in diagnosis of cases where the cause of death is uncertain, even in 
the face of confirmed bacteremia. A postmortem study from Sweden reported the incidence of myocarditis to be 1.06 
% in 12 747 consecutive autopsies (51) and in the UK histologically proven myocarditis was seen in 1.8%, of cases 
younger than 18 years. In the latter study 54% of the deaths occurred in infants less than 1 year of age, accounting for 
2% of infant deaths referred for autopsy, compared with around 5% of childhood deaths over the age of 5 years. In 
almost 40% of cases there were no macroscopic cardiac abnormalities, the diagnosis being entirely dependent on 
histological examination of the heart. (52) Our study only reports on postmortems requested by medical teams since 
we do not have access to data from medico legal postmortems. Myocarditis may well however be implicated in cases 
of sudden unexpected death in infancy (SUDI) that are referred to the medical examiners. For a full appreciation of 
the prevalence and incidence of mortality these cases will need to be included in studies in the future. 
 
Despite the high rate of early mortality, the outlook for children who survive the initial admission, is cautiously 
hopeful. Twenty percent of children who attended COPD (12% of total cohort) recovered fully and were discharged 
from cardiology care. The EF normalized in a further 30.4% of children still in care. Despite these good outcomes, the 
long-term mortality may be underestimated due to the high levels of children lost to follow-up (34.7%). Andrews et al 
recently showed that children who survive an initial hospitalization with heart failure from heart muscle disease, have 
a good medium‐term survival (82% overall 1‐year survival but 77% at 5 years and 73% at 10 years, with survival 
conditional on 1‐year survival 94% & 89% at 5 and 10 years respectively). (36) Therefore, despite an increased 
likelihood of death early in their illness trajectory, patients with an acute fulminant presentation should be managed 
aggressively. (39) These data support ongoing access to high care and intensive care for these children since they may 
recover or stabilize, as reported in international data. (36) We did not explore markers of long-term outcome.  
 
Retrospectively assigning causality in this study was in certain cases complicated by the incomplete evaluation, 
especially for metabolic and autoimmune diseases as well as the lack of access to genetic testing. It is clear that 
clinicians should be further educated on the guidelines to investigate children, as well as the importance of correct and 
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timeous specimen collection necessary as soon as possible after admission. Though 48-60% of DCMO cases in 
children are idiopathic, (22,25) cases need to be extensively investigated prior to making this diagnosis. After case 
reviews we concluded that presumed viral myocarditis occurred in 54 (36.7%) and a cause could not be determined in 
31 (26.5%). Due to incomplete evaluation we were however not able to classify them as idiopathic. In the study from 
RCWMCH 87% of children had presumed viral myocarditis and idiopathic DCMO occurred in 13%. (24) Despite the 
known correlation of respiratory PCR with viral myocarditis, finding viruses in the respiratory tract does not 
necessarily indicate they are causal. A positive PCR may be related either to shedding, or due to a respiratory 
infection that may trigger admission in a child with established myocardial dysfunction. Multiple viruses were found 
in a large number of children, and where viral pathogens were identified, 38.9% had 2 or more viruses. Like other 
studies we found that adenovirus, parvovirus, enteroviruses and CMV virus were common. The role of CMV and 
rhinovirus is not clear in the cause of myocarditis. In the case of CMV, it was considered the potential cause in this 
study if there was no other cause found and there was a confirmed viraemia of more than Log 3. Locally we have used 
a VL of >60 000 to suggest significant pulmonary infections in children with HIV, and Log 3 (VL 1000 copies per 
ml) is widely reported as a significant level of viraemia in children undergoing transplantation. There are no cut-offs 
for myocarditis and interpreting CMV viral load is complicated. Where CMV was considered in the cohort as the 
potential cause, the median age of children was younger than 6 months, which indicated acute infection. 
 
Myocardial dysfunction is a well-known complication of human immune deficiency virus infection. (4, 26, 27) Of the 
80 children tested in the cohort, twenty-four (20.5%) of the children were HIV exposed and of these 7 (29.2%) were 
HIV-infected. Four of the 7 HIV-infected children (57.1%) were on ARVs. A large proportion (31.6%) of children 
were not tested for HIV and in a setting of high HIV prevalence this needs to be addressed. Four of the HIV-infected 
children included in this study died.  
Ten percent of the children were being treated for TB disease and were on therapy at the time of diagnosis. 
Unfortunately more detailed information was not available and collected on these children, but this may indicate that 
these children had chronic symptoms causing them to seek health care. One could postulate that in some of these 
children, symptoms may have been due to cardiac disease rather than TB. Of interest is also the number of children 
with compressed airways on the CXR. We did not confirm whether this finding was in children with TB diagnosis at 
the time of presentation. Cardiac enlargement may cause airway compression (53) and in settings with a high TB 
prevalence, TB may be the incorrect diagnosis. 
 
As in all retrospective studies there are a number of limitations. Despite an extensive initial case search through 
Clinicom, the ICU and ward databases, and all COPD files, there may have been sampling errors and missed cases.  
Children were occasionally coded with the incorrect ICD 10 codes as well. Retrospective data extraction from clinical 
records occasionally did not allow for complete data sets, as there was information missing, illegible handwriting and 
incomplete documentation in the doctors’ notes. Assessing the given causes and re-assigning the causes for the study 
definitions was also complex. 
 
The strengths of this study include that it is the first at TBH in Cape Town, and provides information of an interesting 
cohort of South African children. In addition, we feel that apart from rheumatic heart disease, acquired disorders and 
other diseases of the heart muscle are under appreciated in the current climate. There is a focus on the rapid and 
effective management of correctable structural lesions of the heart. This study is the first to confirm our suspicions. 
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We are now collaborating in a registry that will prospectively evaluate and enrol these children, and the data will form 




This study strikingly shows the high mortality in our local cohort, and this emphasises the need for a high index of 
suspicion of myocarditis in the emergency room setting. Similarly rapid PICU access and specialist intervention is 
needed to improve mortality. Secondary bacterial infections are important contributors to death in this cohort and 
must always be considered. Although we may be underestimating the total deaths in this cohort, the survival after the 
first admission was fair and supports the current recommendation to provide a full set of interventions to these 
patients. Adherence to the myocarditis/DCMO investigation protocol needs to be improved to allow for improved 
diagnosis and prognostication. Future studies in local and under resourced settings are needed to allow for prevalence 
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Year 1994 1999 2003 2006 2006 2009 2010 2010 2012 2014 2014 2016 
TOTAL N= 34 32 773 11 128 62 33 94 169 61 45 95 
Viruses + (%) 76% 34% 35% 45% 68% 68% 64% 33% 22% 18% 64% 87% 




24%  13% 9%  6% 24% 11% 9%  7%  
CMV1 3% 9% 2%     11% 0.6% 3%   
EBV2   0.4% 9%    2%     
Echovirus       6%  2%    
Hepatitis B        1%     
Herpes Zoster    9%     0.6%    
HHV63     13%        
HSV4 6%  0.6%     2%   2%  
Influenza A or B   0.6%   3% 6%  6% 2% 2%  
Measles         0.6%    
Metapneumovirus       3%      
Mumps       3%  0.6%    
Parainfluenza      13%       
Parvovirus B19   0.8% 18% 38% 2%  1% 1% 13% 18% 20% 
Rhinovirus       3%    2%  
RSV5   0.1%    15% 1%     
Multiple Viruses  6%  3%  12% 4%      4% 34% 
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Appendix 2: List of ICD 10 codes used in the electronic data base searches 
I40 Myocarditis  
• I40.0 Infective myocarditis 
• I40.1 Isolated myocarditis 
• I40.8 Other acute myocarditis 
• I40 9 Acute myocarditis, unspecified 
• I41.0 Myocarditis in bacterial diseases classified elsewhere 
• I41.1 Myocarditis in viral diseases classified elsewhere 
• I41.2 Myocarditis in other infectious and parasitic diseases classified elsewhere 
• I41.8 Myocarditis in other diseases classified elsewhere 
 
Cardiomyopathy 
• I42.0   Dilated cardiomyopathy 
• I42.1 Obstructive hypertrophic cardiomyopathy 
• I42.2 Other hypertrophic cardiomyopathy 
• I42.3 Endomyocardial (eosinophilic) disease 
• I42.4 Endocardial fibroelastosis 
• I42.5 Other restrictive cardiomyopathy 
• I42.7 Cardiomyopathy due to drugs and other external agents 
• I42.8 Other cardiomyopathies 
I42.9 Cardiomyopathy, unspecified 
 
Cardiomyopathy in diseases classified elsewhere 
• I43.0 Cardiomyopathy in infectious and parasitic diseases classified elsewhere 
• I43.1 Cardiomyopathy in metabolic diseases 
• I43.2 Cardiomyopathy in nutritional diseases 
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Appendix 3: Case report form  
 
    DATA COLLECTED CODE 
PATIENT NUMBER 1/2/3 ETC 
 
DOB 
AGE AT DIAGNOSIS (DAYS) 
MONTHS AT DIAGNOSIS 






WEIGHT AT DIAGNOSIS 
Z SCORE WEIGHT FOR AGE 
MALE (1) FEMALE (2) 
(IN KG) 
METRO AREA INSIDE TBH (1) 
KHAYELITSHA (2) 
OUTSIDE TBH (3) 
NOT AVAILABLE (4) 
DATE OF DIAGNOSIS OF 
MYOCARDITIS/DCMO 






CONFIRMED DIAGNOSIS (WITH ECHO/HISTO) 
 
DIAGNOSIS ADMISSION DATE 
DIAGNOSIS DISCHARGE/DEATH DATE  
 
NUMBER OF DAYS 1ST ADMISSION 
 
DIED ON 1ST ADMISSION 
DIED ON SUBSEQUENT ADMISSION 
DIED DURING STUDY IN HOSPITAL 
SURVIVED 





IF DEAD: DATE OF DEATH  
 
AGE AT DEATH (DAYS OLD) 
AGE AT DEATH (MONTHS) 
 




TIME TO DEATH (FROM DIAGNOSIS) (DAYS) 
FURTHER ADMISSIONS 
FURTHER ICU ADMISSIONS 
ADMISSIONS REQUIRING INOTROPES 
ADMISSIONS REQUIRING VENTILATION 
 
MOST RECENT CLINICAL ENCOUNTER 
TIME OF FOLLOW UP (DAYS) 
TIME OF FOLLOW UP (MONTHS) 
YEAR/MONTH/DATE 
CLINICAL ALONE (1) CLINICAL AND ECHO (2) 
ECHO, CLINICAL AND POST MORTEM (3)  
POST MORTEM ALONE (4) 
CLINICAL AND PM (5) 
CLINICAL, ECHO, BIOPSY (6) 
 
YES (1) NO (2) 
 





NO (1)  YES (2) 
NO (1)  YES (2) 
NO (1) YES DIED IN HOSPITAL (2) 
NO (1)  YES (2) 
0=SURVIVED 
1=DIED 1ST ADMISSION 








COPD (1) GGR (2) G10 (3) G9 (4) G7 (5) G3 (6) PICU 
(7) OTHER (8) NOT DOCUMENTED (9) RXH (10) 
DID NOT DIE (11) 
 
0/1/2/3 (DAYS) 
YES (1) NO (2) INFO NOT CLEAR (3) 
YES (1) NO (2) INFO NOT CLEAR (3) 
YES (1) NO (2) INFO NOT CLEAR (3) 











LESS THAN 5% (1) 6-10%(2) 11-20% (3)  
LESS THAN 20% (11) 
 
21-30% (4)  







THROMBUS EVER ON ECHO 
EFFUSION EVER ON ECHO 
MOST RECENT ECHO 
 
 
EF ON MOST RECENT ECHO 
 
 
31-40% (5) 41-50% (6) 51-55% (7) MORE THAN 55% 
(8)  NO ECHO DONE (9)  
INFO NOT AVAILABLE  (10) 
 
YES (1) NO (2) NO ECHO DONE (3) NOT DOC(4) 




LESS THAN 5% (1) 6-10%(2) 11-20% (3)  
LESS THAN 20% (11) 
 
21-30% (4)  
31-40% (5) 41-50% (6) MORE THAN 51-55% (7) MORE 
THAN 55% (8)  
NOT AVAILABLE (9) NO ECHO DONE (10) 
 
NUMBER OF ADMISSION TO TBH AFTER 
DIAGNOSIS 2008-2015 
1/2/3 ETC  
NUMBER OF ICU ADMISSION TO TBH AFTER 
DIAGNOSIS 2008-2015 
1/2/3 ETC  
NUMBER OF COPD VISITS AT TBH 2007-2015 
 
TOTAL NUMBER OF ECHOS ON ECHO 
SYSTEM 





CAUSE OF MYOCARDITIS/DCMO  ACUTE VIRAL INFECTION (1) HIV DISEASE (2) 
DRUG ARV (3) DRUG CHEMO (4) IMMUNIZATIONS 
(5) METABOLIC  (6) ARRHYTHMIA (7)  
UNIDENTIFIED (7) OTHER (8) 







YES (1) NO (2) NOT DOCUMENTED (3) 
 
HIV POSITIVE  YES (1) NO (2) TEST NOT DONE (3) 
ON ARVS AT TIME OF DIAGNOSIS 
ADMISSION 
 
YES (1) NO (2) N/A (3) NOT SURE (4) 
 
TIME OF SYMPTOMS PRIOR TO 
PRESENTATION 
1 DAY (1) 2 DAYS(2) 3 DAYS(3)  
4-6 DAYS (4) 7-10 DAYS (5) 10-14 DAYS (6)   
2-4 WEEKS (7)  MORE THAN A MONTH (8) 
NOT DOCUMENTED (9) 
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DELAY IN DIAGNOSIS PRESENTATION 
 





MORE THAN 2 HEALTHCAREVISITS 
 
ADMITTED TO ANOTHER HOSPITAL FIRST 
 
MORE THAN 4 DAYS SYMPTOMS 
 
DIFFERENT DIAGNOSIS IN NOTES PRIOR TO 
MYOCARDITIS/DCMO 
YES (1) NO (2) NOT CLEAR (3) 
 
MULTIPLE CLINIC/GP VISITS PRIOR (1) ADMITTED 
AT ANOTHER HOSPITAL PRIOR (2) NOT 
APPLICABLE (3) DIFFERENT DIAGNOSIS 
SUSPECTED (4)  
MORE THAN 5 DAYS SX (5) 
 
YES (1) NO (2) NOT CLEAR (3) 
 
YES (1) NO (2) NOT CLEAR (3) 
 
YES (1) NO (2) NOT CLEAR (3) 
 




PLACE OF ARRIVAL IN TBH COPD (1) GGR (2) G10 (3) G9 (4) G7 (5) G3 (6) PICU 
(7) OTHER (8) NOT DOCUMENTED (9) 
AFTER ARRIVAL AT TBH TIME TO 
DIAGNOSIS SUGGESTED IN NOTES 
IMMEDIATE (1) HOURS (2) DAYS (3) WEEKS (4) 




YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3)  
YES (1) NO (2) NOT DOCUMENTED (3) 
 




YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
INTUBATED ON ARRIVAL YES (1) NO (2) NOT DOCUMENTED (3) 
ANY OXYGEN SUPPORT ON ARRIVAL YES (1) NO (2) NOT DOCUMENTED (3) 
SYSTOLIC HYPOTENSION ON ARRIVAL  
 








YES (1) NO (2) NOT DOCUMENTED (9) 
 
YES (1) NO (2) NOT DOCUMENTED (9) 
 
YES (1) NO (2) NOT DOCUMENTED (9) 
 
 
GCS ON ARRIVAL 15/15 (1) 11-14 (2) 9-10 (3) 8 OR LESS (4) NOT 










TACHYCARDIA FOR AGE 
MORE THAN 160  (1) 





LESS THAN 60 (7) 
NOT DONE (8) 
 
YES (1) NO (2) NOT DOCUMENTED (8) 
 
RR 0-12 (1) 13-18 (2) 19-25 (3) 26-35 (4) 36-50 (5) 51-60 (6) 
MORE THAN 60 (7) VENTILATED (8) 
NOT DOCUMENTED (9) 






ANY HYPOTENSION  
 
ACTUAL LACTATE RESULTS 
RAISED LACTATE (>3) 
 
PH 





(1 OR MORE OF ABOVE +) 
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
 
YES (1) NO (2) NOT DOCUMENTED (9) 
 
1/2/3/4 ETC 
YES (1) NO (2) TEST NOT DONE (7) 
 
ACTUAL PH 




YES (1) NO (2)  TOO LITTLE INFORMATION  (3) 
 









YES (1) NO (2) NOT DOCUMENTED (3) 
 
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3)  
YES (1) NO (2) NOT DOCUMENTED (3) 
YES (1) NO (2) NOT DOCUMENTED (3) 
 
RENAL FUNCTION DONE  
RENAL DYSFUNCTION (RAISED CREATININE) 
YES (1) NO (2) 
YES (1) NO (2) TEST NOT DONE (3) 
ELECTROLYTES DONE 
ELECTROLYTE DYSFUNCTION 
YES (1) NO (2) 
YES (1) NO (2) TEST NOT DONE (3) 
LFTS DONE YES (1) NO (2) 
LFT ABNORMALITIES  (RAISED AST) YES (1) NO (2) TEST NOT DONE (3) 
LACTATE DONE YES (1) NO (2) 
LACTATE RESULT LESS THAN 1 (1)    1.1-3 (2)    3.1-5 (3) 
5.1-7 (4)    7.1-10 (5)    MORE THAN 10 (6) TEST NOT 
DONE (7) REJECTED (8) 
CK DONE YES (1) NO (2) 
CK RAISED YES (1) NO (2) TEST NOT DONE (3) 
TROPONINS DONE YES (1) NO (2) 
TROPONINS RAISED MORE THAN 
0.1UG/LITRE 
YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
BLOOD GAS DONE 
pH  
YES (1) NO (2) 
MORE THAN 7.45 (1)   7.35-7.44 (2) 
7.25-7.34 (3)     7.15-7.24 (4) 
7.0-7.14 (5)    LESS THAN 7 (6) 
TEST NOT DONE (7) 
NOT DOCUMENTED (8) 
BLOOD CULTURE DONE YES (1) NO (2) 
BLOOD CULTURE + YES (1) NO (2) TEST NOT DONE (3) 
ENTEROVIRUS SCREEN + (URINE, STOOL, 
BLOOD) 
 
YES (1) NO (2)  TEST NOT DONE (3) TEST DONE/NO 
RESULT (4) 
COXSACKIE + (2 SPECIMENS IGM/IGG) YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
MUMPS DONE YES (1) NO (2) 
MUMPS IGM+ 
MUMPS PCR + 
MUMPS EITHER + 
YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
RUBELLA DONE YES (1) NO (2) 
RUBELLA IGM + YES (1) NO (2) TEST NOT DONE (3) 
PARVO B19 TESTED YES (1) NO (2) 
PARVO B PCR + 
PARVO B IGM+ 
PARVO EITHER + 
YES (1) NO (2) TEST NOT DONE (3) REJECTED (4) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
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CMV SEROLOGY DONE 
CMV IGM + 
CMV VL DONE 
YES (1) NO (2) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) 
CMV VL RESULT LDL (1)                LOG LESS THAN 2 (2) 
LOG 2.1-3 (3)     LOG 3.1-4 (4) 
LOG 4.1-5 (5)     LOG MORE THAN 5 (6) 
TEST NOT DONE (7) 
CMV PCR ON URINE DONE YES (1) NO (2) 
CMV URINE PCR + YES (1) NO (2) TEST NOT DONE (3) 
EBV IGM DONE YES (1) NO (2) 
EBV IGM + YES (1) NO (2) TEST NOT DONE (3) 
HERPES SCREEN DONE YES (1) NO (2) 
HERPES SCREEN (IGM OR PCR +) YES (1) NO (2) TEST NOT DONE (3) 




INFLUENZA VIRUS A + 
INFLUENZA VIRUS B + 
INFLUENZA VIRUS C + 
ADENOVIRUS 
RSV+ 
CORONA VIRUS + 
ENTEROVIRUS + 
OTHER VIRUS + 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 
YES (1) NO (2) TEST NOT DONE (3) 












LESS THAN 40% (1)       
41-50% (2) 
51-55% (3)       
56-60% (4)      
MORE THAN 60% (5) 
NO CXR AT DIAGNOSIS (6) 
 
YES (1) NO (2) 
YES (1) NO (2) 
YES (1) NO (2) 
YES (1) NO (2) 
WARD INITIALLY ADMITTED TO  GGR (1)  G3 (2)  G7 (3)  G9 (4)  G10 (5) PICU (6) HIGH 
CARE (7) OTHER (8) NOT ADMITTED (10) 
ICU ADMISSION 
NUMBER OF DAYS IN ICU 
YES (1) NO (2) UNKNOWN (3) 
1/2/2/4 ETC 
VENTILATED 
IF YES: NO OF DAYS 
YES (1) NO (2)  
1/2/3/4 ETC 
 
NONINVASIVE OXYGEN SUPPORT YES (1) NO (2)  NOT DOC/NO INFO (3) 
INOTROPES YES (1) NO (2)  
DOPAMINE/DOBUTAMINE YES (1) NO (2)  
ADRENALIN/NOR-ADRENALIN YES (1) NO (2)  
MILRINONE YES (1) NO (2)  
TOTAL NUMBER OF DAYS OF INOTROPES 
>>2 INOTROPES 
1/2/3/4/5/6/7/8/9/10 ETC  
YES (1) NO (2) 
DIURETICS USED (LASIX +-SPIRO) YES (1) NO (2)  
ACE-INHIBITOR USED YES (1) NO (2)  
B-BLOCKER USED YES (1) NO (2)  
DIGOXIN   YES (1) NO (2) 
ANY STEROIDS YES (1) NO (2)  
POLYGAM RECEIVED YES (1) NO (2)  
B VITAMINS/CARNITINE GIVEN  YES (1) NO (2)  
ASPIRIN USED  YES (1) NO (2)  
CLEXANE/WARFARIN USED 
TRANSFUSED ANY BLOOD PRODUCTS 
 
YES (1) NO (2)  
YES (1) NO (2) 
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MOST RECENT COPD VISIT DATE 
 
AGE AT FOLLOW UP (DAYS) 
AGE AT FOLLOW UP (MONTHS) 
 
 
WEIGHT AT FOLLOW UP 
WEIGHT Z-SCORE AT FOLLOW UP 
 
ANY SYMPTOMS REPORTED 
 
 
DISPLACED APEX (CARDIOMEGALY) 
SIGNS OF CCF 
MEDICATIONS 














YES (1) NO (2) NOT DOCUMENTED (3) N/A (DIED(4) 
NEVER FOLLOWED UP (5) 
 
YES (1) NO (2)           
YES (1) NO (2) 
YES (1) NO (2) 
YES (1) NO (2) 
YES (1) NO (2) 
YES (1) NO (2) 
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Appendix 4: Tygerberg Hospital DCMO workup guideline 
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Appendix 5: Ethics approval 
 
20-Oct-2014 Carkeek, Katherine Janita KJ 
Ethics Reference #: S14/07/154 
Title: 
Outcomes of children admitted to Tygerberg Children's Hospital with Myocarditis and Dilated 
Cardiomyopathy between 1 January 2008 and 30 May 2014. 
Approval Notice New Application 
Dear Dr Katherine Janita Carkeek, 
The New Application received on 14-Jul-2014, was reviewed by Health Research Ethics Committee 2 via 
Committee Review procedures on 06-Aug-2014 and has been approved.  Please note the following 
information about your approved research protocol: 
Protocol Approval Period: 06-Aug-2014 -06-Aug-2015 
Present Committee Members: 
Davids, Mertrude MA Fernandez, Pedro P Blaauw, Renee R Botha, Philip PR Barsdorf, Nicola N 
De Roubaix, John JAM Engelbrecht, Susan S Edwards, C E Holgate, Sandi SL Hansoti, Bhakti B Weber, 
Franklin CFS 
Please remember to use your protocol number (S14/07/154) on any documents or correspondence with the 
HREC concerning your research protocol. Please note that the HREC has the prerogative and authority to 
ask further questions, seek additional information, require further modifications, or 
monitor the conduct of your research and the consent process. 
After Ethical Review: 
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted 
to the Committee before the year has expired. The Committee will then consider the continuation of the 
project for a further year (if necessary). Annually a number of projects may be selected randomly for an 
external audit. Translation of the consent document to the language applicable to the study participants 
should be submitted. 
Federal Wide Assurance Number: 00001372 Institutional Review Board (IRB) Number: IRB0005239 
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it 
pertains to health research and the United States Code of Federal Regulations Title 45 Part 46. This 
committee abides by the ethical norms and principles for research, established by the Declaration of 
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical 
Research: Principles Structures and Processes 2004 (Department of Health). 
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Provincial and City of Cape Town Approval 
Please note that for research at a primary or secondary healthcare facility permission must still be obtained 
from the relevant authorities (Western Cape Department of Health and/or City Health) to conduct the 
research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western Cape 
Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health 
(Helene.Visser@capetown.gov.za Tel:+27 21 400 3981). Research that will be conducted at any tertiary 
academic institution requires approval from the relevant hospital manager. Ethics approval is required 
BEFORE approval can be obtained from these health authorities. 
We wish you the best as you conduct your research. For standard HREC forms and documents please 
visit: www.sun.ac.za/rds 
If you have any questions or need further assistance, please contact the HREC office at 0219389207. 
Included Documents: 
Investigator CV (Carkeek) HREC New application form Investigator declaration (Carkeek) 
Protocol Investigator declaration (Rabie) Cover letter HREC general checklist Investigator CV 
(Rabie) Protocol Synopsis 
Sincerely, 
Mertrude Davids  HREC Coordinator Health Research Ethics Committee 2 
Investigator Responsibilities  
Protection of Human Research Participants 
Some of the responsibilities investigators have when conducting research involving human participants are 
listed below: 
1.Conducting the Research. You are responsible for making sure that the research is conducted according 
to the HREC approved research protocol. You are also responsible for the actions of all your co-
investigators and research staff involved with this research. 
2.Participant Enrolment. You may not recruit or enrol participants prior to the HREC approval date or after 
the expiration date of HREC approval. All recruitment materials for any form of media must be approved 
by the HREC prior to their use. If you need to recruit more participants than was noted in your HREC 
approval letter, you must submit an amendment requesting an increase in the number of participants. 
3.Informed Consent. You are responsible for obtaining and documenting effective informed consent using 
only the HREC-approved consent documents, and for ensuring that no human participants are involved in 
research prior to obtaining their informed consent. Please give all participants copies of the signed 
informed consent documents. Keep the originals in your secured research files for at least fifteen (15) 
years. 
4.Continuing Review. The HREC must review and approve all HREC-approved research protocols at 
intervals appropriate to the degree of risk but not less than once per year. There is no grace period. Prior to 
the date on which the HREC approval of the research expires, it is your responsibility to submit the 
continuing review report in a timely fashion to ensure a lapse in HREC approval does not occur. If 
HREC approval of your research lapses, you must stop new participant enrolment, and contact the HREC 
office immediately. 
5.Amendments and Changes. If you wish to amend or change any aspect of your research (such as research 
design, interventions or procedures, number of participants, participant population, informed consent 
document, instruments, surveys or recruiting material), you must submit the amendment to the HREC for 
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review using the current Amendment Form. You may not initiate any amendments or changes to your 
research without first obtaining written HREC review and approval. The only exception is when it is 
necessary to eliminate apparent immediate hazards to participants and the HREC should be immediately 
informed of this necessity. 
6.Adverse or Unanticipated Events. Any serious adverse events, participant complaints, and all 
unanticipated problems that involve risks to participants or others, as well as any research-related injuries, 
occurring at this institution or at other performance sites must be reported to the HREC within five (5) days 
of discovery of the incident. You must also report any instances of serious or continuing problems, or non-
compliance with the HRECs requirements for protecting human research participants. The only exception 
to this policy is that the death of a research participant must be reported in accordance with the 
Stellenbosch University Health Research Ethics Committee Standard Operating Procedures 
www.sun025.sun.ac.za/portal 
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Eth
ics/Application_package All reportable events should be submitted to the HREC using the Serious Adverse 
Event Report Form. 
7.Research Record Keeping. You must keep the following research-related records, at a minimum, in a 
secure location for a minimum of fifteen years: the HREC approved research protocol and all amendments; 
all informed consent documents; recruiting materials; continuing review reports; adverse or unanticipated 
events; and all correspondence from the HREC 
8.Reports to the MCC and Sponsor. When you submit the required annual report to the MCC or you submit 
required reports to your sponsor, you must provide a copy of that report to the HREC. You may submit the 
report at the time of continuing HREC review. 
9.Provision of Emergency Medical Care. When a physician provides emergency medical care to a 
participant without prior HREC review and approval, to the extent permitted by law, such activities will not 
be recognised as research nor will the data obtained by any such activities should it be used in support of 
research. 
10.Final reports. When you have completed (no further participant enrolment, interactions, interventions or 
data analysis) or stopped work on your research, you must submit a Final Report to the HREC. 
11.On-Site Evaluations, MCC Inspections, or Audits. If you are notified that your research will be 
reviewed or audited by the MCC, the sponsor, any other external agency or any internal group, you must 
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